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Molekylære subtyper og overlevelse i en historisk kohort av kvinner med 
brystkreft 
Målsetningen med studiene bak denne avhandlingen var å bidra til bedre klassifisering av brystkreft i 
prognostiske grupper. Arbeidet er basert på en historisk kohort av kvinner med brystkreft med lang 
oppfølging. Fra 1956-1959 ble alle kvinner fra Nord-Trøndelag som var født mellom 1886 og 1928, 
invitert med i et brystkreftscreeningprogram i regi av Kreftregisteret. Av de nesten 26 000 inviterte 
kvinnene, fikk 1393 brystkreft i perioden fra 1961-2008. De fleste av disse kvinnene ble operert, men 
hadde ellers ingen eller lite tilleggsbehandling. Alle tilgjengelige vevsblokker fra disse svulstene ble 
hentet fra arkivet til avdeling for patologi ved St Olavs Hospital.  
Blokker med svulstvev fra 909 av disse kvinnene hadde god nok kvalitet, og disse er inkludert i 
prosjektet. Svulstene ble klassifisert etter histopatologiske typer og differensieringsgrad. Det ble brukt 
immunhistokjemi og in situ hybridisering, som er vanlige metoder innenfor molekylærpatologi, for å 
klassifisere i seks molekylære subtyper (Luminal A, Luminal B (HER2-), Luminal B (HER2+), HER2 
subtype, Basal Phenotype og 5 Negative Phenotype). Videre ble det gjort studier av kjente markører 
hvor prognostisk nytte ikke er avklart.  
Avhandlingen bygger på 3 delprosjekter som er publisert i 3 artikler. I den første studien ble 
prognosen for de ulike molekylære subtypene sammenlignet. Det ble funnet forskjeller mellom 
subtypene der Luminal A hadde best prognose, mens HER2 subtypen og 5 Negative Phenotype kom 
dårligst ut. Det mest interessante var at disse forskjellene var bare tilstedet for svulster med middels 
differensieringsgrad (histopatologisk grad 2) og bare de første 5 årene etter diagnose. 
I den andre studien var målsetning å finne ut om TOP2A kan være til hjelp for å vurdere prognosen av 
brystkreft. TOP2A er et gen på kromosom 17 som koder for proteinet topoisomerase II α. Dette er 
enzymer som regulerer cellulære prosesser som replikasjon og transkripsjon, og som er målprotein for 
en type cellegift (Antracyklin) som er i bruk ved behandling av brystkreft. I denne studien var TOP2A 
sterkt assosiert med hormonreseptor og HER2 som er viktige prognostiske og prediktive markører i 
klinikken i dag, men denne markøren hadde ikke en selvstendig prognostisk betydning. 
I den tredje studien ble prognose for de 2 vanligste histopatologiske typene brystkreft sammenlignet. 
Det ble funnet at lobulær brystkreft grad 2 hadde dårligere prognose enn duktal brystkreft grad 2, men 
prognosen var sammenlignbar med duktal brystkreft av mer aggressiv grad (histopatologisk grad 3). 
De fleste lobulær brystkreftsvulster er negative for bindingsproteinet E-cadherin. E-cadherin brukes i 
klinikken som et diagnostisk hjelpemiddel når det er tvil om en svulst er lobulær eller ikke. I den 
tredje studien ble det funnet at E-cadherin kan være nyttig som en prognostisk markør for lobulær 
brystkreft fordi E-cadherin negativ lobulær brystkreft hadde dårligere prognose enn E-cadherin 
positiv. For duktal brystkreft hadde E-cadherin ingen prognostisk verdi. 
Studiene bak denne avhandlingen kan gi viktige bidrag i forståelsen av brystkreft. Først og fremst kan 
dette bidra til bedre klassifisering av brystkreft, og da spesielt den heterogene gruppen av grad 2 
svulster. Videre er det vist at histopatologiske type kan ha selvstendig verdi som en prognostisk 
markør, og dette kan få betydning for valg av behandling. E-cadherin kan lett implementeres i 
klinikken som en prognostisk markør for lobulær brystkreft. Funnene må bekreftes i videre studier. 
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4. Background 
 
4.1 Introduction 
Breast cancer is the leading cause of death from cancer among women worldwide. Breast 
cancer accounts for one in every four cases of cancer and, in 2012, a total 1.7 million cases of 
breast cancer were diagnosed  [1]. Incidence is highest in developed countries, but is 
increasing in developing countries where breast cancer mortality is relatively higher compared 
to more affluent parts of the world. This may, in part, be explained by late diagnosis and lack 
of optimal  therapy [2]. Figures 1 and 2 show breast cancer incidence and mortality 
worldwide [1]. 
 
 
 
Figure 1 Incidence of breast cancer worldwide [1]. 
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Figure 2. Mortality of breast cancer worldwide [1]. 
 
 
In 2012, 2 956 women were diagnosed with breast cancer in Norway and 645 deaths from the 
disease were registered. Breast cancer is the most common cancer and the second most 
common cause of death from cancer among women in Norway [3]. Figure 3 shows incidence 
for the ten most common cancers and Figure 4 shows the ten most common causes of cancer 
death among women in Norway in 2011 [4].  
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Figure 3. The ten most common cancers among women in Norway in 2011. 
 
 
Figure 4. The ten most common causes of cancer death among women in Norway in 2011. 
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The incidence of breast cancer in Norway has increased from 1960 to 2005. Around 2005 
there was a slight fall in incidence followed by an increase reaching a peak of 3094 in 2011 
(Figure 5). In 2012, 2956 cases of breast cancer were diagnosed [3]. Despite the increase in 
incidence, mortality has declined. A reduction in mortality was first observed in the middle of 
the 1990s, probably due to a combination of earlier diagnosis and the introduction of new 
treatment options [5-7]. In the same period, survival has improved considerably, and, in 2010, 
9 out of 10 women were still living five years after diagnosis (Figure 5).  
 
 
   
Figure 5. Breast cancer incidence, mortality and survival in Norway from 1965 to 2012 [3]. 
 
Survival is usually expressed as a 5-year rate which is the percentage of people still alive 5 
years after diagnosis. Relative survival is the percentage of the patient population who are still 
alive after 5 years divided by the percentage of the general population alive at the end of the 
same time period. However, breast cancer patients have a higher risk of death compared to the 
general population more than 20 years after diagnosis [8] and 5-year survival is therefore a 
limited description of breast cancer prognosis.  
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4.2 Causes and risk factors of breast cancer  
Epidemiological studies have identified a number of risk factors, but the causes of breast 
cancer are not known. The correlations between potential causes, risk factors and breast 
cancer are complex and not fully understood. Risk factors and possible causes are largely 
outside our influence. A relationship between various risk factors and breast cancer in general 
has been demonstrated, and more recently, more specific studies of associations between risk 
factors and different subtypes of breast cancer have been published [9-12].  
Among breast cancer risk factors beyond the individual`s control are weight and length at 
birth, intrauterine oestrogen exposure, adult height and hereditary breast cancer risk. The 
same applies to mammographic breast density which is also associated with an increase in 
risk of developing breast cancer [13, 14]. The proportion of hereditary breast cancer is 
estimated to be between 5 and 10 % [15-17]. Mutations in the BRCA1 and BRCA2 genes are 
autosomal dominant by nature and account for 45 – 50 % of hereditary breast cancer. For a 
large proportion, the BRCA1 mutations lead to triple negative breast cancer (hormone receptor 
negative and HER2 negative breast cancer). The risk of developing various breast cancer 
subtypes differs between ethnic groups. For example, African American women have a higher 
risk of basal phenotype or basal-like breast cancer [18, 19].  
Alcohol consumption and body weight are established modifiable risk factors associated with 
life style. A dose-response association between alcohol consumption and risk of breast cancer 
has been shown, but the mechanisms are not known [20, 21]. Premenopausal obesity and 
postmenopausal obesity are associated differently with breast cancer risk. Premenopausal 
obesity has been shown to have a protective effect while postmenopausal obesity is associated 
with higher risk [22, 23]. Exposure to radiation could also be classified as a modifiable risk 
factor.   
Reproductive factors such as early onset of menarche, high age at first birth, non-parity and 
late age at menopause are associated with higher risk of breast cancer [22, 24, 25]. These risk 
factors seem mainly to be linked to hormone receptor positive breast cancer [9, 22]. Breast 
feeding may lower the risk of some subtypes of breast cancer [26]. Pregnancy leads to a 
transient increased breast cancer risk followed by a prolonged protective effect [27-29]. These 
factors are linked to endogenous oestrogens although the mechanisms are not clarified [30].  
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Exogenous hormones have been shown to have an impact on breast cancer risk. Menopausal 
hormonal therapy (MHT) and hormonal contraception are associated with higher breast 
cancer risk [31-33]. The doses of both have been modified considerably since their 
introduction and this may have lead to some reduction of the increased risk. The combination 
of oestrogen and progestagen entails a higher risk than oestrogen alone which in itself is 
probably responsible for a very modest increase in risk [34, 35]. 
Several of the risk factors are linked to exposure to endogenous and exogenous oestrogen and 
the observed increased risk is mainly associated with hormone receptor positive breast cancer.  
For hormone receptor negative subtypes of breast cancer, associations with risk factors are 
much less clear [9, 36]. The complexity of this field and interactions between the different 
risk factors makes studies and interpretation of studies difficult. 
 
4.3 Advances in breast cancer treatment  
The treatment of breast cancer remained largely unchanged until the latter half of the 20th 
century. Surgical resection of breast cancer tumours was described as early as in the 1th 
century by Celsus [37]. In more recent times, William Halsted is credited for performing the 
first radical mastectomy in the 1890s. However, Charles Moore advocated mastectomy en 
bloc as early as 1867 [38]. In 1882 William Banks recommended routine axillary clearance 
when treating breast cancer [38].  
In the 1950s, radical mastectomy versus simple mastectomy was discussed [39]. Still, radical 
mastectomy with removal of the pectoralis major muscle remained the treatment of choice 
until approximately 1970, followed by simple mastectomy which spared the muscle and 
reduced morbidity [40, 41]. As early as in the 1950s and 1960s and parallel to the discussions 
regarding the extent of mastectomy, clinical trials comparing mastectomy with breast 
conserving surgery followed by radiotherapy were carried out [42]. Breast conserving therapy 
for selected patients was gradually implemented from the 1970s, but was not accepted in 
Norway until the 1990s [43]. A number of studies have shown similar survival for breast 
conserving surgery and mastectomy [44-48]. More recently, even large tumours have been 
treated with breast conserving surgery following the development of more advanced 
oncoplastic techniques or after down-staging with neoadjuvant chemotherapy. 
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The sentinel node (SN) technique is another important advance in the surgical treatment of 
breast- and other cancers. The basis for this method is the hypothesis that the lymphatic 
drainage from the breast passes through one or more gate-keeper or sentinel lymph nodes in 
the axilla and to a lesser extent the retrosternal region [49, 50]. With lymphoscintigraphy 
and/or blue dye (methylene blue, patent blue v or isosulfan blue), the SN can be detected and 
removed for histopathological examination [51]. If no metastasis is found, further axillary 
surgery is not performed. For approximately 75 % of patients axillary clearance is thus 
avoided [52] and postoperative morbidity and risk of lymphoedema is reduced [53, 54]. For 
patients with clinical negative axilla and micrometastasis to the SN, axillary clearance can be 
omitted [55-57]. 
Advances leading to improvement of prognosis have been achieved with the advent of 
adjuvant therapy. Indications for and type of chemotherapy have changed over the years from 
perioperative chemotherapy recommended to all [58] to the more individually tailored 
treatment protocols of today [59]. For patients with positive hormone receptor status, 
endocrine therapy has been shown to improve survival [60]. From around 1970, endocrine 
therapy was indicated in cases of metastatic breast cancer [61]. In 1975, measurement of 
oestrogen receptor (ER) was introduced facilitating better selection of patients for treatment 
with tamoxifen thus increasing its use as an adjuvant therapy alternative [62]. Recent 
publications have documented better survival for ten years treatment versus five years for 
premenopausal women [63]. However, decreasing effect of treatment over time may be a 
disadvantage. Furthermore, poor compliance may also reduce benefit [64, 65].    
Targeted therapy against HER2 is one of the major advances made in adjuvant breast cancer 
treatment in recent years. The monoclonal antibody trastuzumab was the first anti-HER2 
agent approved for breast cancer treatment [66]. The treatment has improved prognosis for 
HER2 positive breast cancer when used in combination with chemotherapy. More recently, 
even more potent inhibitors of HER2 have been introduced. Anti-HER2 therapy has been 
shown to be useful in the adjuvant, neo-adjuvant and metastatic setting [66].  
Radiation therapy is of importance in the control of local and regional breast cancer and thus 
impacts long-term survival [67, 68]. Radiotherapy is given based on breast cancer stage and 
as an integral part of breast conserving treatment. Prognostic biomarkers are not decisive in 
determining radiotherapy.  
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4.4 Morphology 
The structural and functional tissue in the breast consists of epithelium arranged in lobules 
and ducts and their surrounding connective tissue. In normal breast tissue, the epithelium 
consists of two layers: the epithelial (luminal) layer lining the lumen and the myoepithelial 
(basal) layer between the epithelial layer and the basal lamina [69]. These two layers consist 
of three cell types [70]: luminal and basal cells in the epithelial layer and myoepithelial cells 
in the myoepithelial layer. In the non-lactating breast, the stromal elements (fat cells and 
fibrous connective tissue) comprise the majority of the breast volume. Both epithelium and 
stroma are hormonally responsive, and differentiation is dependent on the influence of 
oestrogen and on the stromal-epithelial interaction [71]. The proportion of fat and connective 
tissue varies among individuals, and changes throughout life under the influence of 
physiological and hormonal factors [72].  
 
a)   b)    
Figure 6. Normal HES-stained breast tissue. a) A normal lobule (HES, 100x). b) Clear cell change in 
the myoepithelial layer (HES, 1000x). Photo: A M Bofin 
 
Embryologic development from the milk lines is independent of steroid hormones early in 
fetal life. From 15 weeks, further differentiation is dependent on testosterone. Secretory 
activity is induced by maternal and placental steroid hormones and prolactin in the last weeks 
of fetal life. The maternal hormonal influence on the infant disappears during 1-2 months after 
birth, and further breast development is postponed until puberty [72]. Under the influence of 
oestrogen at the onset of puberty, growth and differentiation of both epithelium and stroma 
occurs. Prolactin, growth hormones and glucocorticoids also contribute. Further hormonal 
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changes cause differentiation of the breast tissue during pregnancy and lactation. With the 
onset of the menopause, glandular atrophy gradually occurs. 
In addition to the luminal ductal cells and the myoepithelial cells, there is also evidence of the 
existence of breast stem cells dispersed in the glandular tissue [71, 73]. The function of 
normal stem cells is self-renewal and maintenance of homeostasis in tissue [74, 75]. The 
normal stem cells must be able to undergo frequent mitosis and migrate within the organ. 
These are also qualities characteristics of cancer cells.  
 
4.5 The development of cancer 
The mechanisms of uncontrolled cellular proliferation are only partly understood. Cancer 
development is a multistep process reflected in intratumoural heterogeneity where the various 
cell types interact and the stroma and microenvironment participate actively [76]. Two 
important hypotheses are the stem cell theory of cancer and the theory of somatic evolution in 
cancer [77].  
In the cancer stem cell theory, cancer stem cells have the ability to proliferate extensively and 
new cancer cells originate only from cancer stem cells [78]. Other non-stem cancer cells 
proliferate and contribute to the progression of the disease, but they cannot sustain the 
development of cancer independent of the stem cells. Liu et al demonstrated breast cancer 
stem cells in distinct mesenchymal-like and epithelial-like states [79]. Gene-expression profile 
studies of these states showed similar expression patterns for the different molecular subtypes 
suggesting the same cell of origin. 
In the theory of somatic evolution in cancer, a neoplasm is the result of sequential mutations 
occurring because of genetic instability, environmental factors and/or other events that 
together lead to uncontrolled cell growth [77, 80]. In this theory, all cancer cells have the 
same potential for further growth under the same exposure [81].  
Both theories are explanations of tumour heterogeneity and the one does not exclude the other 
[77].  
Breast cancer arises from the epithelium, probably most frequently in the terminal duct 
lobular unit. Histopathologic examination of proliferative lesions may reveal a variety of 
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morphological entities such as usual hyperplasia, atypical hyperplasia, carcinoma in situ and 
invasive carcinoma. The different intraductal proliferative entities are associated with varying 
degrees of increased risk of developing invasive carcinoma [82]. The work in this project is 
restricted to invasive breast carcinomas. 
 
4.6 Histopathological types 
Breast cancer is a heterogeneous disease or group of diseases and this is reflected in the 
microscopical findings. Breast cancer is divided into morphological groups based on both the 
growth pattern and the appearance of the cells in the tumours. Pathologists have a long history 
of seeking to classify breast cancer into meaningful groups of similar pattern by assessment of 
HES-stained sections [83]. Classification in histopathological types is done according to 
World Health Organization (WHO) Classification of Tumours [82]. Updated versions of the 
WHO classification system have been published regularly since 1968 (Scarff, R. W. & 
Torloni, H. Histological Typing of Breast Tumours (WHO, Geneva, 1968)).The terminal duct 
lobular unit is the anatomical origin of the majority of breast carcinoma regardless of 
histopathological type.  Although it is recognized that prognosis may differ for the various 
types, histopathological type is currently not decisive for treatment in Norway. 
Tumours with distinct histopathological characteristics in HES-stained sections are classified 
as special types and approximately 30 different types and subtypes have been described [82, 
84]. The special types account for 25 % of all breast carcinomas [85, 86]. Approximately 75 
% of breast carcinomas fail to fit as special type [83] and are classified as invasive breast 
carcinomas of no special type (NST). This type or group of types is commonly referred to as 
invasive ductal carcinoma (IDC) and shows considerable variation in growth pattern and cell 
appearance.  Figure 7 a and b show examples of invasive breast carcinomas of NST.  
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a)  b)   
 Figure 7. a) Invasive carcinoma of no special type (HES) 100x b) 600x. Photo: A M Bofin 
 
Invasive lobular carcinoma is the second most common type and most frequent of the special 
types comprising 5–15 % of all breast cancers. Invasive lobular carcinoma is defined as a 
tumour composed of non-cohesive cells growing in a dispersed fashion or in cell lines 
(“Indian file” pattern) in a fibrous stroma [82]. Classic microscopic features are small cells, 
uniform nuclei, infrequent mitoses and the absence of glandular structures. There are a 
number of variants making classification more difficult and some of these variant are 
infrequent. Mixed types, such as tubulolobular carcinoma also occur. 
 
a)    b)  
Figure 8. Invasive lobular carcinoma with “Indian file” pattern (HES). a) 200x b) 600x                 
Photo: A M Bofin 
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Tubular carcinoma (2 %), mucinous carcinoma (2 %), medullary carcinoma (< 1 %), 
metaplastic carcinoma (0.2 – 5 %), papillary carcinoma (rare) and neuroendocrine carcinoma 
(< 1 %) are examples of other less frequent histopathological types [82]. Tubular carcinoma 
entails a favourable prognosis and is characterized by well-differentiated tubular structures in 
most of the tumour. In mucinous carcinomas, clusters of small uniform cells are seen floating 
in varying amounts of extracellular mucin. Capillary fragments are also seen. Medullary 
carcinoma is characterized by pushing borders, high-grade nuclei, lack of glandular structures 
and prominent lymphoid infiltration. Medullary breast cancer occurs more frequently among 
breast cancer patients with BRCA1 mutation [87, 88]. In metaplastic carcinomas, the epithelial 
cells may differentiate into squamous cells or mesenchymal-like cells of various appearances. 
Some of the special types are infrequent or rare, and therefore studies of each of these types 
are difficult.  
 
a)  b)  
c)    d)  
Figure 9. Invasive carcinoma, special types. a) Tubular carcinoma (HES, 400x), b) Mucinous 
carcinoma (HES,400x), c) Metaplastic carcinoma (HES, 600x) and d) Ductal carcinoma with 
medullary feature (HES, 200x). Photo: A M Bofin 
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4.7 Histopathological grading 
Breast cancer is classified into histopathological grades which reflect the degree of 
differentiation of the tumour cells. Histopathological type and grade give complementary 
information regarding tumour features and prognosis [83]. Grading is usually done on full 
face HES-stained sections. The most commonly used method is the Nottingham Grading 
System (NGS) [89] which is  a modification of the original Scarff-Bloom-Richardson grading 
system [90]. Histopathological grade provides prognostic information and is decisive for 
treatment. Even in the current genomic and molecular era, lymph node status, tumour size and 
histopathological grade are still considered to be the three strongest prognostic determinants 
in breast cancer [91, 92]. In experienced hands and under standardized conditions, the 
reproducibility is modest to good [89, 93, 94]. 
Figure 10 shows examples of invasive ductal carcinoma, grades 1 and 3. Three features are 
considered and scored in the NGS (see Table 1): The proportion of tumour with tubule 
formation, the number of mitoses and the degree of variation in nuclear size and shape are 
assessed and allotted a score. The sum of the scores for the three components generates the 
grade.  
Tubular structures: The tumour is given a score of 1 if more than 75 % is composed of 
glandular structures and 3 if tubules are found in less than 10 % of the tumour. A pitfall in this 
assessment is shrinkage artefact due to poor fixation, and clearly visible lumina are important 
[89].  
Nuclear pleomorphism: Nuclei are assessed for size, shape and variations of these features. 
The high-scoring nuclei are often vesicular with multiple nucleoli. Some histopathological 
types, such as lobular carcinoma, are characterized by small or relatively small nuclei and 
consequently result in a low score (1 or 2). Scoring of nuclear pleomorphism is to a certain 
extent subjective, and interindividual variation occurs  [95].  
Mitoses: The scoring criteria for the mitotic count are more well-defined [89, 95]. The 
number of mitoses is dependent on microscopic field diameter in the microscope used by the 
pathologist, and the guidelines in Figure 11 are followed.  
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Grade 1 (score 3-5) represents the most differentiated and least aggressive tumours, grade 2 
(score 6-7) moderate and grade 3 (score 8-9) the most poorly differentiated, most aggressive 
tumours.  
 
a)    b)  
 
Figure 10. Invasive ductal carcinoma. a) Tubular structures in grade 1 ductal carcinoma (HES, 400x). 
b) Profound nuclear pleomorphism in grade 3 invasive ductal carcinoma (HES, 600x). Photo: A M 
Bofin                    
   
 
 
   
 
Table 1. Feature considered when grading according to Nottingham Grading System, table slightly 
modified after Elston and Ellis [89].  
 
Feature Score 
Tubule formation 
     Majority of tumour (>75 %) 
     Moderate degree (10-75 %) 
     Little or none (<10 %) 
 
1 
2 
3 
Nuclear pleomorphism 
     Small, regular uniform cells 
     Moderate increase in size and variability 
     Marked variation 
 
1 
2 
3 
Mitotic counts  
     Score 1-3 dependent on microscope field area.  
     Guidelines in Figure 11 [96] 
 
1 
2 
3 
25 
 
    
Figure 11. Guidelines for grading of breast cancer tumours according to Nottingham Grading System 
[97]. 
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4.8 Detection of biomarkers in breast cancer 
 
Changes in cells can be studied at several points along the molecular biological pathway using 
appropriate methods. The Central Dogma of Molecular Biology was stated by Francis Crick 
in 1956 [98] and restated in 1970 [99]. This is a statement of sequential information 
transferred from DNA to RNA to proteins, but never in the opposite direction from protein to 
DNA. Figure 12 illustrates DNA, RNA and protein as three points on the molecular biological 
pathway. In this project, DNA is studied by in situ hybridisation (ISH) and proteins by 
immunohistochemistry (IHC).  
 
 
 
 
 
 
 
 
 
 
 
Fig 12. The molecular biological pathway. ( K. Stern from D.G. Nathan Genes, Blood, and 
Courage: A Boy Called Immortal Sword 1995 Harvard University Press). 
 
4.8.1 Immunohistochemistry  
IHC is a method that unites histology, immunology and chemistry [100]. Immunological 
methods are used to visualise the distribution and localisation of specific antigens in 
histological sections. IHC is used in clinical diagnostics, for prognostication of disease and for 
prediction of treatment [70]. The method was introduced in 1941 by Albert Coons [101] on 
fresh frozen tissue. Fluorescence was initially used for visualization. The method was further 
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developed for use on Formalin-fixed, paraffin-embedded (FFPE) tissue and with peroxidase 
antibody conjugation enabling assessment under a light microscope [102, 103].  
Specific antibodies are marked with a label visible by light or fluorescent microscopy and 
target antigens are detected by specific interaction between antibodies and antigens. The 
specific location on the antigen with affinity to the antibody is referred to as the epitop. To 
restore reactivity between antibody and epitop, reversing the effect of formalin fixation is 
necessary. This process is referred to as antigen retrieval or epitop retrieval, and is usually 
achieved by enzymatic reactions or by heating the sections [100, 104, 105]. After the 
introduction of retrieval techniques in the 1990s an increased number of antigens have 
become detectable [100].  
IHC staining can be done as a one-step staining where the antibody with a visible label reacts 
with the epitop. An indirect staining method is more sensitive and more commonly in use, see 
Figure 13. The primary antibody is unlabelled and the target epitop is visualized by a 
secondary labelled antibody. Monoclonal or polyclonal antibodies can be used. Monoclonal 
antibodies require more resources in production than polyclonal, but are more specific 
because they recognize only one epitop within an antigen. Polyclonal antibodies can interact 
with several epitops within the same antigen and can be more robust than monoclonal 
antibodies when preanalytical conditions are unknown. However, non-specific staining may 
occur. 
 
Figure 13. Immunohistochemistry: Indirect staining method. Illustration: MJ Engstrøm 
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Table 2 summarize steps and variables in the IHC-method. There are some limitations to be 
aware of. Preservation of the antigen is obviously an important factor for success. Formalin is 
the most used fixation solution. However, the pathologist or researcher has little control or 
influence over time from removal to fixation, the fixation time, solution volume relative to the 
tissue size or transport of the tissue. These issues may be of importance when interpreting 
immunohistochemical staining and represent potential pitfalls in the present project.  
 
Table 2. Steps and Variables in an Immunohistochemical Test [100].  
 
In addition to the variables in the table, it is important to bear in mind that storage temperature 
for the sections after cutting may compromise antigen retrieval. 
 
4.8.2 In situ hybridization 
ISH is a method used to detect a specific DNA or RNA sequence in a section of tissue (in 
situ). The method makes it possible to see the localization of the sequence of interest in the 
tissue and to assess the amount or number of copies. This technology combines cytogenetics 
and molecular genetics [106]. Figure 14 shows the principles of the method. Double-stranded 
DNA, both probe and target sequences, are first denatured at high temperature. The probe, a 
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labelled complementary DNA or RNA, is added and hybridized to the target DNA or RNA 
sequence while the sections are annealed. The target sequences can be metaphase 
chromosomes or, as in ISH on tissue sections, interphase chromosomes and specific loci on 
chromosomes.  
To visualize and locate the sequence of interest, the label is fluorescent (FISH), chromogenic 
(CISH) or silver (SISH). There is good correlation between these methods [107-109]. Using 
different coloured labels, multiple sequences may be localized simultaneously (multicolour 
ISH) [110].  
 
 
Figure 14 In situ hybridization. (National Human Genome Research Institute (NHGRI) 
http://www.genome.gov/12514471 by artist Darryl Leja). 
 
In breast cancer this technique is used to detect HER2 amplification and FISH has been the 
method of choice for primary assessment of HER2-status or for confirmation of IHC [111, 
112]. Other ISH methods have been shown to provide accurate and consistent results and are 
increasingly used [113, 114]. However, the American Society of Clinical Oncology (ASCO) 
and the College of American Pathologists (CAP) recommend validation of bright-field ISH by 
30 
 
comparing to a FISH-assay approved by the American Food and Drug Administration (FDA) 
before introducing these methods [115].  
The possibility of visualising signals for several probes simultaneously or separately by 
changing filters is an advantage of FISH. Potential drawbacks of FISH are fading of the 
signals and difficulty in recognizing tumour tissue. CISH utilizing a chromogen rather than a 
fluorokrom opens for brightfield microscopy and tissue morphology is more easily 
appreciated. However, in some cases, signals may be difficult to enumerate due to close 
proximity or overlapping, especially in dual-colour CISH.  
 
 4.8.3 Gene expression analysis 
To measure the amount of specific DNA or RNA, complementary DNA (cDNA) microarray 
technology can be used. In these methods, the complementarity of the two DNA strands is 
utilized. The DNA sequences from the specimen to be examined are denatured, and the cDNA 
is labelled with fluorescent dye (usually red). The reference cDNA is commonly from cell 
culture and is labelled with a different fluorescent dye (usually green). The mixture of these 
cDNA is hybridized to a microarray (Figure 15). Each spot in the microarray contains specific 
DNA sequences (probes) in known positions. The cDNA from the sample and from the 
reference are added to the microarray, and after hybridization to the probes, red spots express 
up-regulated genes in the sample and green spots express up-regulated genes in the reference.  
The measurement of gene expression by cDNA is called gene expression analysis or gene 
expression profiling. The gene expression profile of a tumour represents the molecular 
signature unique for that tumour, and this signature may correspond to outcome for the patient 
[116]. Classification of breast cancer tumours based on gene expression profiling of a high 
number of genes has provided a deeper understanding of breast cancer [117, 118].  
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Reference cDNA                        Tumour cDNA 
 
              cDNA microarray                                                                    Scanned microarray 
Fig. 15. Schematic description of cDNA microarray analysis of DNA copy-number changes [119].  
 
 
 
4.9 Biomarkers in breast cancer 
There are a number of prognostic and predictive biomarkers in clinical use in breast cancer. 
Treatment guidelines are based on hormone receptor-, HER2- and proliferation (Ki67) status 
in addition to histopathological grading, tumour size and lymph node status. These 
biomarkers are considered essential in prognostication of breast cancer. In addition, hormone 
receptor and HER2 are important predictive factors. 
Great advances have been made in research on novel biomarkers and new classification 
systems in addition to improved methods and technology. However, research using well-
known markers may provide useful knowledge in new areas contributing to better 
understanding of disease.  
 
 4.9.1 Hormone receptors 
Hormone receptors are receptors that can bind to specific hormones and initiate multiple and 
complex signalling pathways in the cells. In breast cancer they play a major role as prognostic 
and predictive indicators [120, 121]. The function of these steroid receptors is to control 
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transcription of genes involved in cellular processes like growth and differentiation. The term 
hormone receptor in the context of breast cancer mainly refers to oestrogen receptor (ER) and 
progesterone receptor (PR). In addition, androgen receptor (AR) is frequently expressed in 
breast cancer [122] but its clinical impact is not clarified. ER and PR are localised to the 
parenchymal cell nuclei, mainly the luminal epithelial cell [123, 124].  
Historically, measurement of ER in breast cancer tumours was done on fresh frozen tissue by 
an enzyme immune assay. In Norway, this method was used until late in the 1980s. After 
introduction of immunoperoxidase staining, ER could be assessed in FFPE and in smaller 
tumours. The Department of Pathology in Trondheim was among the first to introduce the 
method [125].  
Currently, IHC are used to evaluate all breast carcinomas for ER and PR status. Most breast 
cancer tumours (70 – 80 %) are hormone receptor positive. According to guidelines from the 
American Society of Clinical Oncology (ASCO) and the College of American Pathologists 
(CAP), tumours are considered ER or PR positive when ≥ 1 % of the tumour cells show 
positive nuclear staining [126]. At the biannual St. Gallen Breast Cancer Conference, 
recommendations regarding diagnostic and treatment of breast cancer are given based on 
consensus meetings. In 2009, it was recommended that a tumour is considered ER positive if 
there is any detectable ER [127]. There is no strict evidence for a cut-off of ≥ 1 % [128]. 
 
4.9.1.1 Oestrogen receptor  
In normal breast tissue approximately 7 % of the nuclei show positive staining for ER and the 
ER positive cells are often singly distributed surrounded by ER negative cells [72, 124]. 
Signals from oestrogens are mediated through the nuclear receptors ERα and ERβ [129]. The 
two subtypes of ER regulate growth and development of mammary tissue through a fine 
balance of oestrogen signalling in cells [130]. Binding of oestrogen to ER leads to changes in 
gene transcription regulating cell growth, differentiation, apoptosis, and angiogenesis [121, 
131].  
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ERα is the classic ER receptor assessed by IHC in breast cancer tissue. The discovery of ERβ 
was published in 1996 [132, 133] but the clinical significance of ERβ has not yet been 
clarified. Expression of ERβ is shown to improve the prognosis of breast cancer patients 
receiving adjuvant tamoxifen [134] and in the future assessment of ERβ may be an option.  
 
a)  b)    
Figure17. Invasive carcinoma NST. a) HES stained (600x). b) ER positive nuclei (600x).  Photo: A M 
Bofin. 
 
 
 
 
 
Figure 16. Normal breast tissue stained for ER and 
smooth muscle actin (SMA). ER positive nuclei 
surrounded by ER negative nuclei in ductal 
epithelium. SMA stained myoepithelial cells (1000x).  
Photo: A M Bofin                    
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4.9.1.2 Progesterone receptor  
ER and PR are usually co-expressed [123]. This co-expression is regarded as an indication of 
intact and functional ER since ER regulates the expression of PR [82]. There are two isoforms 
of PR (PRA and PRB) and for the biological effect of progesterone both isoforms are 
activated [135]. PR provides limited additional prognostic and predictive information. 
However, ER positive, PR negative breast cancer cases may have a poorer response to 
endocrine treatment compared to cases in which both receptors are expressed [136]. 
 
4.9.2 HER2 
Human epidermal growth factor receptor 2 (HER2) is one of four receptors in the epidermal 
growth factor receptor (EGFR) family and the gene is located on chromosome 17q12-21 [137-
139]. The other three receptors in the family are epidermal growth factor receptor (EGFR, 
HER1, erbB1), HER3 (erbB3), and HER4 (erbB4) [140, 141]. Epidermal growth factor (EGF) 
binds to EGFR on the cell surface and stimulates cell growth, proliferation and differentiation, 
and normal expression of EGFR is essential for normal cell growth and cell survival [142].  
 
 
Figure 18. The four members of the EGFR family: EGFR, HER2, HER3 and HER4. HER2 is 
activated by heterodimerization with one of the other members of the family. The activation leads to 
initiation of cascade resulting in cell proliferation and survival [141].             
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HER2 overexpression in breast cancer is associated with poor prognosis. However, 
trastuzumab, a humanized monoclonal antibody targeting HER2 receptor, is an effective 
treatment for HER2 positive breast cancer in combination with chemotherapy [142]. 
Overexpression of the HER2 protein has been shown to be strongly correlated to HER2 gene 
copy number [138, 143, 144] and HER2 status can be assessed by either IHC or ISH. There is 
an ongoing discussion regarding the optimal testing regime [113]. 
IHC is commonly used as the initial test for HER2 [145]. There are many commercially 
available antibodies and good agreement is shown for the most commonly used antibodies 
[145]. The membrane staining is semiquantitatively assessed according to strict criteria. 
Recommendations regarding assessment of IHC given by National Health Services Breast 
Screening Programme (NHSBSP) in United Kingdom are shown in Table 3 [146]. Tumours 
are considered HER2+ when IHC membrane staining score is 3+, negative when 0 or 1+ and 
equivocal when 2+.  
 
Table 3. Recommended IHC scoring method from National Health Service Breast Screening 
Programme [146].  
Score to report  HER2 protein overexpression assessment Staining pattern 
0 Negative No staining is observed, or membrane staining in less 
than 10% of tumour cells.  
 
1+ Negative A faint/barely perceptible membrane staining 
is detected in more than 10% of tumour cells. The 
cells are only stained in part of the membrane.  
 
2+ Borderline A weak to moderate complete membrane staining is 
observed in more than 10% of tumour cells.  
 
3+ Positive  A strong complete membrane staining is observed in 
more than 10% of the tumour cells.  
 
 
In cases with equivocal IHC, HER2 testing by ISH is recommended [113]. Interpretation of 
HER2 after ISH is done by estimating gene to chromosome ratio after counting signals for 
both in a minimum of 20 nonoverlapping tumour cell nuclei [144]. A gene to chromosome 
ratio ≥ 2.0 is regarded as HER2 amplification in most guidelines [113, 144]. ASCO/CAP 
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recommend recounting when ratio is between 1.8 and 2.2 [147]. The most recent revision of 
guidelines from ASCO/CAP (2013) differ slightly from those of NHSBSP regarding IHC and 
ISH and are shown in Table 4. 
 
Table 4. Recommendations from ASCO/CAP regarding IHC and ISH for HER2. The table is slightly 
modified [115] 
2013 HER2 Test Guidelines and Recommendations from ASCO/CAP 
Must report HER2 test result as positive for HER2 if: 
● IHC 3+ based on circumferential membrane staining that is complete, intense 
● ISH positive based on: 
Single-probe average HER2 copy number ≥ 6.0 signals/cell 
Dual-probe HER2/CEP17 ratio ≥ 2.0 with an average HER2 copy number ≥ 4.0 signals per cell 
Dual-probe HER2/CEP17 ratio ≥ 2.0 with an average HER2 copy number < 4.0 signals/cell 
Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number ≥ 6.0 signals/cell 
Must report HER2 test result as equivocal and order reflex test (same specimen using the alternative 
test) or new test (new specimen, if available, using same or alternative test) if: 
● IHC 2+ based on circumferential membrane staining that is incomplete and/or weak/moderate and 
within > 10% of the invasive tumor cells or complete and circumferential membrane staining that is 
intense and within ≤ 10% of the invasive tumor cell 
● ISH equivocal based on: Single-probe ISH average HER2 copy number ≥ 4.0 and < 6.0 signals/cell 
Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number ≥ 4.0 and < 6.0 signals/cell 
Must report HER2 test result as negative if a single test (or both tests) performed show: 
● IHC 1+ as defined by incomplete membrane staining that is faint/barely perceptible and within ≤ 
10% of the invasive tumor cells 
● IHC 0 as defined by no staining observed or membrane staining that is incomplete and is 
faint/barely perceptible and within ≤ 10% of the invasive tumor cells 
● ISH negative based on: Single-probe average HER2 copy number < 4.0 signals/cell 
Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number < 4.0 signals/cell 
Must report HER2 test result as indeterminate if technical issues prevent one or both tests (IHC and 
ISH) from being reported as positive, negative, or equivocal. 
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Figure 19 show examples of HER2 CISH (a) and FISH (b). 
 
a)     b)   
Figure 19. High grade amplification of HER2. a) CISH in biopsy (1000x). Signals for HER2 are red, 
and signals for chromosome 17 centromere are blue. b) FISH in cytology (400x). Signals for HER2 
are red, and signals for chromosome 17 centromere are green. Photo: A M Bofin. 
 
 
 4.9.3 Ki67 
Ki67 is a nuclear protein present in the S, G2 and M phases of the cell cycle. In addition, Ki67 
may be found in the G1 phase after mitosis [148]. Ki67 is regarded as a proliferation marker 
[148, 149]. The function of this protein has not been clarified, but a number of publications 
have shown prognostic value both in early stage [150, 151] and advanced [152] breast cancer. 
Ki67 is assessed by IHC. MIB1 is the most commonly used antibody [153].  
Despite widespread use as a prognostic marker in a variety of different cancers types, 
estimation of Ki67 remains controversial and as yet, unresolved. To reduce intra- and 
interlaboratory variability there are given guidelines for analysing and reporting of Ki67 
[154]. Still, direct comparison between laboratories and studies is difficult due to 
inconsistency in counting methods and results in assessment of Ki67 [153]. Area for counting 
and number of counted nuclei varies in different publications [154]. In the present project, 
Ki67 positive staining nuclei were counted in “hot spot” areas or best countable areas of the 
TMA cores. A minimum of 500 tumour cell nuclei were assessed, and the results were given 
as percentage positive cell nuclei. 
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Figure 20. Invasive breast carcinoma with positive nuclear staining for Ki67 (MIB1) (600x). Photo: A 
M Bofin 
 
4.9.4 Cytokeratin 5 (CK5)  
Cytokeratins (CK) are cytoplasmic proteins important for the cytoskeleton of most eukaryote 
cells. CKs of different molecular weights  can be used to distinguish between cell type and 
differentiation status [155]. In normal breast tissue, expression of different CKs can be used to 
distinguish between cell types [123]. Cytokeratin 5 (CK5) is expressed in myoepithelial and 
basal cells, and is one of the markers used to identify the basal phenotype/basal-like breast 
cancer. CK5 is assessed by IHC and is readily available although it is not in clinical use. A 
combination of CK5 and CK6 (CK5/6) is more commonly used but CK5 has a higher 
sensitivity for detection of the  basal phenotype [156].  
There are no accepted guidelines for the assessment of CK5. Some authors use a staining 
index (SI) where staining intensity and the proportion of cells with cytoplasmic staining are 
assessed separately and give a score. The scores are multiplied and the result is expressed as 
SI [157, 158]. Staining intensity is graded as 0 (no staining), 1 (weak), 2 (moderate) and 3 
(strong). The proportion of positive staining cells is scored as 1 (<10 %), 2 (10–50 %) and 3 
(>50 %). There is no consensus on cut off for CK5. In some papers, SI 1-9 is considered 
positive [157-159]. In this project, the tumours were considered to be negative for CK5 when 
SI was 0–1 and positive when the SI was 2–9 [160]. 
The H-score is another method which may be used to assess IHC. In this method, the extent of 
immunoreactivity is evaluated by the following formula giving a score between 0 and 300: 3 x 
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proportion (in percent) of strongly stained cells + 2 x proportion (in percent) of moderately 
stained cells +  proportion (in percent) of weakly stained cells [156, 161]. 
 
 
Figure 21. Invasive breast carcinoma stained for CK5. Positive cytoplasmic staining in tumour cells 
(1000x). Photo: A M Bofin 
 
4.9.5 Epithelial growth factor receptor 1 
Epithelial growth factor receptor 1(EGFR) is a transmembrane glycoprotein belonging to the 
HER-family of tyrosin kinase receptors [162], and is encoded by the HER1-gene. Activation 
of EGFR plays a central role in several important intracellular signalling pathways regulating 
cell proliferation, growth and survival. A simplified overview of the signalling pathway 
including inhibitory signals like PTEN and MKP1 is shown in Figure 22. Overexpression of 
EGFR in epithelial tumours may lead to more aggressive growth and invasion [162] and is 
associated with a poorer prognosis [163].  
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Figure 22. EGFR signalling pathway [164] 
 
EGFR is not assessed routinely in breast cancer, but is of interest in research and has been 
shown to identify the tumours of basal phenotype among the triple negative tumours [165]. In 
Paper I, EGFR was assessed by IHC membrane staining, and scoring was done according to 
Table 5. SI was calculated with staining intensity multiplied by the proportion positive cells 
and a SI ≥ 2 was regarded as EGFR positive. Figure 23 shows a EGFR positive case. 
 
 
 
Table 5.  Assessment of EGFR. Staining index (SI) is score for staining intensity multiplied by score 
for proportion of positive cells. 
Staining 
intensity 
0 = no 
staining 
1 = faint, incomplete 
membrane positivity 
2 = moderate intensity; 
circumferential 
staining 
3 = strong intensity; 
circumferential 
staining 
Proportion 
positive cells 
1a = < 1 % 1 = < 10 % 2 = 10 - 50 % 3 ≥ 50 % 
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Figure 23. Invasive breast carcinoma stained for EGFR. Positive cytoplasmic staining in tumour cells 
(1000x). Photo: A M Bofin. 
 
4.9.6 E-cadherin  
E-cadherin (E-cad) is a protein in epithelial cells involved in cell-to-cell adhesion and 
suppression of invasion and metastasis [166]. During embryogenesis, E-cad play a role in the 
formation of tissue [167]. This transmembrane protein extends from the extracellular space 
through the cell membrane and into the cytoplasm [168]. The function of E-cad is dependent 
on a number of other proteins in the E-cadherin complex. The intracellular domain binds to 
and interacts with p120 catenin and b-catenin which in turn bind and interact with other 
intracellular proteins.  
In current diagnostic breast pathology, IHC for E-cad may be used to distinguish lobular 
neoplasia, lobular carcinoma in situ and invasive lobular carcinoma from ductal carcinoma in 
situ and invasive carcinoma of no special type in difficult cases [168]. E-cad positive cases 
show a continuous membrane staining with moderate to strong intensity while focal or pearly 
expression is regarded E-cad negative [168]. Most lobular tumours are E-cad negative.   
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a) b)   
Figure 24. Invasive lobular carcinoma at magnification 400x. a) HES staining. b) IHC showing E-cad 
positive status in the same tumour. A M Bofin 
 
4.9.7 TOP2A 
TOP2A is a gene close to HER2 on chromosome 17. Topoisomerase II α is the protein product 
of TOP2A and the molecular target of anthracycline treatment. The function of the 
topoisomerase enzymes is the regulation of cellular processes like replication and 
transcription [169, 170]. A number of publications have shown frequent co-amplification of 
TOP2A and HER2 [171, 172]. However, amplification of TOP2A has also been shown to 
occurs independent of HER2 amplification [169]. The prognostic and predictive value of gene 
copy number changes in TOP2A has not been clarified and TOP2A is not included in the 
clinical biomarker repertoire.  
Detection of TOP2A gene copy number changes can be done by in situ hybridization. Gene to 
chromosome ratio is estimated based on signal counting in a minimum of 20 non-overlapping 
tumour cell nuclei. Cases with ratio ≥ 2 are usually considered TOP2A amplified, and TOP2A 
may be deleted when the gene to chromosome ratio ≤ 0.8 [173, 174]. Definition of monosomy 
is more controversial [137, 175]. In Paper II, only one signal for both gene and chromosome 
in more than 75 % of the recorded nuclei was defined as monosomy for TOP2A. Deletion and 
monosomy were grouped together and defined as TOP2A gene copy number loss. 
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Figure 25. FISH with probes for chromosome 17 centromere and TOP2A showing increased copy 
number of TOP2A in invasive breast cancer (600x). Photo: A M Bofin 
 
4.10 Tissue microarray 
Tissue microarray (TMA) is a high through-put method that enables rapid analyses of a high 
number of specimens under the same conditions. The method was first described by Battifora 
in 1986 [176] and can be used to study genetic or molecular markers. The technique has since 
been modified and improved and a description of the procedure in current use was published 
in 1998 [177]. The use of the method has increased in recent years [178].  
TMA is a collection of biopsies from FFPE tissue blocks and may comprise tumour tissue or 
normal tissue. TMA blocks are constructed by extracting tissue cores from the tissue of 
interest and inserting them into a recipient block. The most common core sizes are 0.6 – 1.0 
mm, and each block may contain as many as 1000 cores [179]. From the TMA blocks, 
sections are cut and stained for routine staining, IHC and ISH. Construction of TMA is 
illustrated in Figure 26. 
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Figure 26. TMA construction in our laboratory. The area for TMA is selected by a pathologist on a 
full-face HES section. 1 mm cores are punched from the donor block and transferred to the recipient 
block. Sections are cut from the recipient blocks and staining is performed. Figure by Linda A. 
Dyrnes. 
 
There are a number of benefits of this method. The opportunity to analyse multiple specimens 
at the same time is the main advantage. This applies primarily to research, but clinical 
laboratories with high numbers of specimens may benefit from this method. IHC and ISH 
techniques can be done on a high number of cases with small amounts of tissue and reagents 
facilitating economic use of both. Tissue utilization of large series can be maximized under 
uniform reaction conditions, and positive and negative controls can be included in the TMA.  
There are some limitations to be aware of. TMA construction is labour intensive. Equipment 
is expensive and experienced users are required. Carcinomas are often heterogeneous and the 
cores in the TMA may not represent the whole tumour. This challenges the selection of areas 
in the donor tumour and the results of the analyses may be influenced. The users must be 
aware of the balance between use and conservation. However, donor paraffin blocks can still 
be used for full face sectioning after TMA-sampling (Figure 27). Loss of cores in the recipient 
blocks occurs. To ensure tumour representativity and avoid loss of cases, more than one core 
can be selected. In this project, three cores were selected from each case and spot loss was < 
10 % and case loss < 4 % [180] . 
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4.11 Preanalytical conditions 
Guidelines have been established to ensure standardized handling of tissue and cellular 
material prior to histopathological examination. The intention is standardization of all steps 
from surgical excision or biopsy to interpretation in order to avoid sources of errors. These 
guidelines encompass preanalytical, analytical and postanalytical conditions to minimize 
variability and tissue damage [126, 181]. However, in research on archival tissue information 
regarding preanalytical conditions is often lacking and all results must be evaluated in light of 
this limitation.  
Histopathological examination is usually performed on FFPE tissue. The purpose of fixation 
is to limit or stop enzymatic degradation and preserve the tissue structure. The ability of 
formalin to fixate tissue has been known since the 1890s [182]. Interpretation of HES-sections 
is dependent on sufficient fixation. In IHC, inadequate fixation may result in false negative 
reactions and thereby false negative biomarker status [183].  
Sample size, tissue type and the amount of fixative are important factors for adequate fixation. 
The time from removal to fixation should not exceed 1 hour, and the optimal tissue fixation 
time is 6 – 72 hours, depending on the size of the sample [126]. Too short fixation time is the 
most important limitation of the quality of the tissue. Some recommend a minimum of 24 
hours [184]. Recommendations regarding formalin volume varies, but a formalin-volume to 
1 mm 
Figure 27. Full-face section from a 
donor block showing defects after 
core extraction. There is no damage 
to surrounding tissue (HES,20x). 
Photo: A M Bofin 
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tissue-volume ratio between 10:1 and 20:1 is the most commonly recommended volume 
[185]. Detailed procedures must be in place and their implementation is vital for optimal 
tissue handling. 
There are variations in routines regarding the handling of biopsies and surgical specimens 
between institutions, within institutions and over time.  
 
 
5. The aims of the study 
The main aims of this study were to reclassify breast cancer tumours from a historic cohort of 
women into molecular subtypes based on surrogate markers for gene expression analysis, and 
to investigate whether this classification gives more precise prognostic information compared 
to histopathological grade. Further objectives were to explore the prognostic value of TOP2A 
in breast cancer and to study prognosis in invasive lobular carcinoma.  
More specifically, the aims of each paper were as follows: 
Paper I: To compare molecular subtyping by IHC and ISH with conventional 
histopathological grading in breast cancer in order to determine whether molecular subtyping 
provides more information regarding outcome.  
Paper II: To study the frequency of TOP2A copy number change in breast cancer and to 
explore the prognostic value of these changes. 
Paper III: To compare the prognosis for ILC and IDC and to evaluate the prognostic value of 
histopathological grading, molecular subtypes and E-cad in ILC.   
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6. Material and methods 
 
6.1 Study population 
 
6.1.1 Description of the cohort 
The women in this cohort were invited to participate in a breast cancer survey organized by 
the predecessor of the Norwegian Cancer Society in the period 1956-1959 [186, 187]. The 
intention of the survey was to evaluate clinical breast examination as a screening method for 
early breast cancer detection. All women aged 20-69 years by January 1, 1956 (born in the 
period 1886-1928) living in three Norwegian Counties (Nord-Trøndelag, Aust-Agder and 
Vestfold) were invited. The long follow-up of this cohort has facilitated a number of studies 
of risk of breast cancer [9, 188-190], gynaecological cancer [189, 191] and thyroid cancer 
[192]. 
In addition to clinical examination conducted by a physician, the women were interviewed by 
a trained nurse or physician. The interview was carried out according to a structured 
questionnaire mainly focused on reproductive history. The youngest women were excluded 
due to incomplete reproductive history and difficulties in identification because of changes in 
family name after marriage. A total of 25 897 women from Nord-Trøndelag County were 
invited to participate in the survey.  
In the period from January 1, 1961 to end of 2008, 1393 women in the Nord Trøndelag cohort 
were diagnosed with breast cancer. Of these, tissue was not available for 448 cases. For 276 
patients, the operation specimens were sent for histopathological examination in other 
laboratories and were not available. In some cases tissue blocks were missing for unknown 
reasons. In the archives of the Department of Pathology and Medical Genetics, St. Olav’s 
Hospital, Trondheim University Hospital, Norway, FFPE tissue was available for 945 cases. 
Some cases were excluded because of insufficient quality of the FFPE tissue, and 909 cases 
were included in the study. Of these, only biopsy was available for 79 cases. Figure 28 shows 
the study population.   
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Figure 28. Flow chart showing number of cases in the study and reasons for exclusion (Paper I) [160]. 
 
6.1.2 Follow-up 
All women diagnosed with breast cancer were followed from the date of diagnosis to the date 
of death from breast cancer, death from any other cause or to the end of follow-up (December 
31, 2010), whichever came first.  
 
6.1.3 Special characteristics of this historic cohort 
Apart from the clinical examination offered during the survey, no organized screening for 
breast cancer was available to the women in this cohort in the follow-up period. In Norway, 
mammography screening was conducted as a pilot project in four counties from 1995-1996. 
The public screening program is governmentally funded and was gradually implemented in all 
counties from 1998 to 2004 [193]. In Nord-Trøndelag, all women in between 50-69 years of 
age have been invited to mammography every other year since 2001. The youngest women in 
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the cohort in the present study were 73 years of age in 2001. Hence, the breast cancer cases in 
this cohort are mainly clinical detected.  
Menopausal hormonal therapy (MHT) has been available since the late 1950s. From 1990 to 
about 2000, MHT was in common use. There was a rapid increase in the use of oestrogen 
replacement therapy during and after menopause in Norway from 10 % in 1992 [194] to 30 % 
in 2002 [195]. Most of the women in this study population have probably not used MHT. The 
oldest women were 75 years of age in 1961 and the youngest were 50 years of age in 1978 
when MHT were introduced in Norway [196]. Some of the youngest may have had hormone 
replacement therapy. However, in the 1980s there was a very modest use of MHT in Nord-
Trøndelag [196]. Oral contraceptives were introduced in Norway in 1967 [197], however, 
their use in the study cohort  must have been negligible due to age and time period.  
There has been a great improvement in breast cancer treatment over the past 10 to 20 years. 
However, for a large proportion of the women in this project, current modern treatment for 
breast cancer was not an option due to the time period in which they were diagnosed. Patients 
diagnosed with breast cancer in the era of modern treatment, did not qualify for additional 
treatment regimes due to their age. Table 6 and 7 show an overview of treatment options. 
Most of the patients had surgery with mastectomy with or without axillary clearance or 
sentinel node diagnostics. Reliable information regarding hormone therapy is not available 
and the numbers in the table are based on the Norwegian guidelines from the relevant time 
period.  
 
Table 6. Breast cancer therapy given to the patients in the cohort  
 Of all cases (909) 
Mastectomy 731 (80.4 %) 
Breast conserving therapy  99 (10.9 %) 
Only biopsy, no surgical treatment 79 (8.7 %) 
Axillary surgery (clearance or sentinel node) 644 (70.8 %) 
Hormone therapy* 192 (25.6 %)** 
Trastuzumab 0 
Chemotherapy Unknown 
Radiation Unknown 
* Estimated according to guidelines at diagnosis. ** % of the hormone receptor positive cases. 
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Table 7. Breast cancer therapy according to histopathological type. Table from paper III [198]. 
 Invasive ductal 
carcinoma n=611 (%)  
Invasive lobular 
carcinoma n=116 (%) 
Total n=727 
(%) 
Mastectomy 524 ( 85.8) 94 (81.0) 618 (85.0) 
Breast conserving 
therapy  
61 (10.0) 12 (10.4) 73 (10.0) 
Only biopsy, no 
surgical treatment 
26 (4.3) 10 (8.6) 36 (5.0) 
Axillary surgery 
(clearance or 
sentinel node) 
461 (75.5) 81 (69.9) 542 (74.6) 
Hormone therapy* 134 (26.2**) 31 (30.4**) 165 (26.9**) 
Trastuzumab 0 0 0 
Chemotherapy Unknown  Unknown Unknown 
Radiation Unknown Unknown Unknown 
* Estimated according to guidelines at diagnosis. ** % of the hormone receptor positive cases. 
 
This population provides us with a unique opportunity to study a cohort of breast cancer 
patients almost exclusively treated with surgery alone.   
 
6.2 Archives of the department of pathology 
FFPE tissue allows for long-term storage in diagnostic or research biobanks. In Norway, 
FFPE tissue blocks archives have been maintained at the various departments of pathology 
since the 1930s [199]. FFPE tissue should be stored in the dark at room temperature, and thus 
can be preserved for an unlimited period of time [200]. The main challenges for further 
storing are of a logistical and practical character. These archives are exceptional and 
constitute a tremendous potential for medical research, especially when combined with public 
registries and population based surveys.  Legal and ethical regulation of the use of these 
biobanks is practised in Norway [201].  
 
6.3 TMA construction and slide scanning 
TMA blocks were constructed using a Tissue Arrayer Mini-Core® 3 with TMA Designer2 
software (Alphelys). Areas of interest in the HES-stained full-face sections were marked by 
an experienced pathologist. Three 1mm in diameter tissue cores were extracted from 
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peripheral regions of the tumour in the donor blocks and inserted into TMA recipient blocks. 
From the TMA blocks, 4 μm sections were cut and stained. IHC was carried out with 
antibodies for ER, PR, HER2 (CB11), CK5, Ki67, E-cad and EGFR in addition to HES 
staining. All HES- and IHC-stained slides were digitalized using the tissue scanner Ariol TM 
SL-50 3.3 Scan system and analysis station (Genetix) at 5x and 20x magnification. IHC-
stained sections were evaluated and scored by two observers independently using the Ariol 
review station.  
 
6.4 Assay methods and classification 
In all three studies, the REMARK recommendations for reporting in tumour marker studies 
were followed [202]. The assay methods are described in detail in Paper I and supplemented 
in Paper II and III. All immunostaining was done in a DakoCytomation Autostainer Plus 
(Dako). Table 8 shows the sources and dilutions of the primary antibodies used for 
visualization. In Paper I, CISH was used for detection of chromosome 17 centromere/ HER2 
copy number and in Paper II, FISH was used for detection of chromosome 17 centromere and 
TOP2A. 
 
Table 8. Sources and dilutions of primary antibodies used in the studies. 
Antibody Clone Manufacturer Concentration of 
antibody 
Dilution 
ER SP1 Cell marque 33 mg/ml 1:100 
PR 16 Novocastra 360 mg/l 1:400 
HER2 CB11 Novocastra 3.9 g/l 1:640 
Ki67 MIB1 Dako 35 mg/l 1:100 
CK5 XM26 Novocastra 50 mg/l 1:100 
EGFR 2-18C9 Dako Ready to use No dilution 
E-cad NCH-38 Dako 55.2 mg/L 1:100 
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Review and classification of all cases into histopathological types and grades was done on 
full-face sections by two pathologists independently. Areas for TMA were selected and 
marked on the glass slide. Constructions of TMA, cutting and staining were performed by 
biomedical engineers. Assessment of all IHC and ISH markers were done by two researchers 
independently. In case of disagreement the sections were re-examined and consensus reached. 
Cut-off levels were set in accordance with clinical guidelines where possible after review of 
the literature.  
Classification in molecular subtypes was done according to the algorithm in Figure 29.   
 
 
Figure 29. Classification system for molecular subtyping based on surrogate markers, based on Paper I 
[160].  
 
6.5 Norwegian Public Registries and ethical committee 
In Norway, there are a number of public registries that enable population based research. 
Reporting to these registries is mandatory by law and close to completeness is therefore 
ensured. 
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6.5.1 The Central Population Registry of Norway 
The Central Population Registry of Norway was established in 1964 based on a census from 
1960 and includes key information on all individuals who are or have been resident in 
Norway. Information on births, deaths, address, migrations, marital status and citizenship are 
recorded for all Norwegian citizens and all foreigners living in Norway for more than six 
months. Since 1964, all Norwegian citizens have an individual 11-digit birth number 
composed of the date of birth, a three-digit individual number and two check digits. This 
registry gives important population statistics. Data regarding birth, death and emigration were 
obtained from The Central Population Registry for this project [203].   
 
6.5.2 The Cancer Registry of Norway 
The Cancer Registry of Norway was established in 1951 after a proposal from WHO [204]. 
The purpose of the registry was to study the incidence of cancer. From its foundation in 1951 
until 1979, the Cancer Registry of Norway was financed by The Norwegian Cancer Society 
which had income mainly from donations. In 1979, the Norwegian government took over 
financial responsibility [205]. The aim has gradually been expanded to include broader 
research and counselling on health care regarding cancer and prevention of cancer. Reporting 
has been mandatory by law since 1952 [206]. The Registry is one of the most complete 
registries in Europe [207]. Data from the study cohort were linked with the Cancer Registry of 
Norway and confirmation of breast cancer diagnosis and date of diagnosis was made available 
for the project [203].     
 
6.5.3 The Cause of Death Registry of Norway 
When Norwegians die in Norway or abroad, information is registered in the Cause of Death 
Registry of Norway. This registry is complete or close to completes and provides the 
opportunity to follow mortality trends and life expectancy. Data from the registry may be 
given to researchers on application including approval from the Regional Committee for 
Medical and Health Sciences Research Ethics.  
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6.5.4 The Regional Committee for Medical and Health Sciences Research Ethics 
To conduct medical research in Norway, approval from The Regional Committee for Medical 
and Health Sciences Research Ethics for each project is mandatory [208, 209]. There are 
seven regional committees processing applications and when necessary The National 
Committee for Medical and Health Sciences Research Ethics gives advice and considers 
appeals. The basis for the work in these committees is founded in international conventions 
like the Declaration of Helsinki [210]. 
 
6.6 Statistical analyses  
In all the studies, survival analyses were carried out using Kaplan-Meier (KM) methods and 
Cox proportional hazards models. All women in the studypopulation were followed from the 
date of breast cancer diagnosis to the date of death from breast cancer, death from any other 
cause or to the end December 2010, whichever came first. There were no cases with missing 
information due to emigration or other causes. Stata version 12.1 IC for Windows (Stata 
Corp.) were used for all the statistical analyses. 
 
6.6.1 Kaplan-Meier 
To compare Breast cancer-specific survival (BCSS) between groups, the KM-method was 
used. This method is widely used to estimate survival [211]. The KM survival curve reflects 
the probability for survival for a given length of time where time is considered in many small 
intervals. The survival is estimated by multiplying the survival probabilities of each time 
interval [212]. The Log-rank test was used to test the statistical significance of the differences 
between survival curves.  
In KM estimates, it is assumed that life expectancy is the same for patients included early and 
late in the study [211]. This is probably not the case in this study where the women included 
were diagnosed with breast cancer from January 1961 to end of December 2008. In Norway, 
there was a notable increase in life expectancy in the first half of the 1990s. For women in 
Norway life expectancy increased from 73.2 years in 1950 to 83.2 years in 2010 [213]. A 
great proportion of this difference is due to changes in infant and child mortality and did not 
affect the women included in this project.  
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6.6.2 Cox Proportional Hazards Model  
KM and log-rank-test are used to compare two groups for significant difference. However, it 
is not possible to include other independent factors in the analyses. In order to achieve this, 
Cox proportional hazards model was used to compare risk of death from breast cancer 
unadjusted and adjusted for age, stage and time period of diagnosis (10-year intervals). 
Hazard ratios (HR) were calculated with 95 % confidence intervals (CI). In each calculation, 
one group was defined as the reference group and was compared to groups with defined 
characteristics.  
This method of studying the relationship between a known risk factor and the patient’s time of 
death is commonly applied. A possible weakness in this model is the assumption that the HR 
for each explanatory variable is constant over time [214]. Thus, effects of time variation 
cannot be revealed.  
 
6.7 Ethical approval  
The studies were approved by the Regional Committee for Medical and Health Sciences 
Research Ethics (REK, Midt-Norge, ref. nr: 836/2009) and dispensation from the requirement 
of patient consent was granted.  
 
7. Summary of results 
7.1 Paper I: Molecular subtypes, histopathological grade and survival in a historic 
cohort of breast cancer patients 
Paper I is the main work in this thesis and forms the basis for the other studies. A total of 909 
cases were included and all were reviewed and classified according to histopathological grade 
and type. TMAs were constructed and using IHC and ISH as surrogates for genomic analyses, 
all cases were reclassified into the following molecular subtypes: Luminal A; Luminal B 
(HER2-); Luminal B (HER2+); HER2 subtype; Basal Phenotype (BP) and Five Negative 
Phenotype (5NP). The algorithm for molecular subtyping is shown in Figure 29.  
The main findings in the study were significant differences in survival according to molecular 
subtypes with best survival for Luminal A and worst for HER2 and 5NP. However, the most 
56 
 
interesting result was that the significant difference in breast cancer specific survival was only 
found for grade 2 tumours and only the first five years after breast cancer diagnosis. For 
women surviving the first 5 years after diagnosis, there appears to be no difference in survival 
according to molecular subtype or histopathological grade. 
 
7.2 Paper II: TOP2A gene copy number change in breast cancer 
Changes in TOP2A copy number as a prognostic marker has been the subject of a number of 
studies, but its prognostic value has not been clarified. In the present study, the 670 cases 
suitable for TMA and ISH assessment of TOP2A and HER2 copy number status were 
included. TOP2A status was assessed using FISH and HER2 was assessed using CISH. Both 
TOP2A and HER2 were classified as amplified when gene to chromosome ratios were ≥ 2. 
TOP2A deletion (gene to chromosome ratio≤ 0.8) or monosomy (only one signal for both 
gene and chromosome in more than 75% of nuclei) were defined as TOP2A gene loss.  
In this study, TOP2A copy number changes were found in 66 cases (41 with amplification and 
25 with gene loss) and HER2 amplification in 110. Most of the TOP2A amplified cases were 
coamplified with HER2 and the association between TOP2A copy number change and 
hormone receptor positive status was strong.  
The risk of death from breast cancer was significantly higher for HER2 amplified cases. This 
difference was present during the first five years after breast cancer diagnosis as shown in 
Paper I, and was not associated with TOP2A status. The main conclusion of the study was that 
TOP2A is of limited value as a prognostic marker in breast cancer.  
 
 
7.3 Paper III: Invasive lobular breast cancer: The prognostic impact of histopathological 
grade, E-cadherin and molecular subtypes 
The prognosis of ILC compared to IDC is still unclear. In addition, histopathological grading 
of ILC is controversial. E-cadherin is often used to confirm lobular type in difficult cases, but 
its potential as a prognostic marker has not been clarified.  
In this paper the prognosis of ILC was compared with that of IDC. All 727 cases of ILC or 
IDC suitable for TMA were included. Of these, 611 were ductal and 116 were lobular.  
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The proportion of grade 2 tumours among the lobular tumours was much higher than for 
ductal tumours, respectively 85.3 % in ILC and 51.9 % in IDC. Only 6 % of ILCs were 
HER2+, whereas 16.9 % of IDCs were HER2+. As expected, the majority of ILCs had 
negative E-cad status and the majority of IDCs were E-cad positive.  
Based on assessment of grade, ER and HER2, ILC would appear to have good prognosis. 
However, one of the main findings in this study was a poorer prognosis for grade 2 ILC 
compared to grade 2 IDC. BCSS of ILC grade 2 was comparable to that of IDC grade 3. E-
cadherin negative ILC had a poorer prognosis compared to E-cadherin positive ILC and to 
IDC regardless of E-cadherin status. For IDC, E-cad had no prognostic value. E-cadherin in 
ILC may be more useful than histopathological grade in prognostication in ILC.  
 
8. Discussion 
Despite great advances in treatment in recent decades, there is still an urgent need for better 
and more precise prognostication of breast cancer. This thesis is based on a historic cohort of 
women with breast cancer with long follow-up. They were diagnosed with breast cancer in an 
era or at an age where modern treatment modalities were not available, thus providing a 
unique opportunity to study the near natural course of this disease. The main aim was to 
contribute to improved breast cancer prognostication. To achieve this, archival FFPE tumour 
tissue was utilized and IHC and ISH methods were used as surrogates for gene expression 
analyses in molecular subtyping and in studies of other characteristics of breast cancer. 
 
8.1 Discussion of the main findings 
The most important findings were significant differences in survival between the molecular 
subtypes with the best survival for the Luminal A subtype and poorest survival for the HER2 
and 5NP subtypes. These findings are in accordance with the findings of others [215-218] . 
However, in this cohort survival was better for BP compared with 5NP. The high average age 
of the patients in this cohort may, in part, explain this phenomenon. The BP among post-
menopausal women may differ from BP in younger patents.  
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Another interesting finding was the discovery that differences in BCSS between subtypes 
were present only during the first five years after breast cancer diagnosis and only for 
histopathological grade 2. To the best of our knowledge, this has not been described for 
molecular subtypes prior to this study. Risk of relapse and death from breast cancer is highest 
the first five years after diagnosis, and survival curves for patients with ER negative status fall 
rapidly during the first years after diagnosis [219]. Despite this, current five year survival for 
breast cancer is approximately 90 % [3]. However, there is still some risk of relapse after 
many years and an important question is why disease with apparently good prognosis may 
remain dormant for many years and then relapse. Negative prognostic factors appear to be of 
less significance after the first five years. The clinical impact of this is still unclear. Currently, 
diagnostic tools capable of identifying patients with apparently good prognosis but high long 
term risk of recurrence are missing.  
Histopathological grading is an important prognostic tool in breast cancer. Several validation 
studies have been performed [220] and histopathological grade is highly decisive for adjuvant 
therapy. Interlaboratory and interpersonal inconsistence has caused discussions, but 
standardization of the method and experienced pathologists have improved the reproducibility 
[221]. However, grade 2 tumours constitute 30 % - 60 % of the breast carcinomas [222], and 
the heterogeneity of these tumours is well known. Gene profile studies have shown distinct 
gene profiles for histopathological grade 1 and 3, but a heterogeneous profile for grade 2 that 
represents a mixture of grade 1 and 3 [222]. Better prognostication of grade 2 tumours is 
required and molecular subtyping may be useful.  
In this cohort of breast cancer patients with a near natural course of the disease, invasive 
lobular carcinoma has a poorer prognosis compared to invasive ductal carcinoma. The 
majority of ILC are grade 2 but their prognosis is significantly poorer that of IDC grade 2.  In 
Norway, histopathological type is not included as a parameter in treatment guidelines. 
Patients with grade 2 ILC should probably be classified in same prognostic group as grade 3 
IDC. However, at present, it is unclear whether the ILC patients would benefit from more 
adjuvant therapy and further research is needed to elucidate this point.  
The histopathological types are distributed differently. Invasive breast carcinoma of no 
special type occurs far more often than the other types. This means that most studies are 
performed on invasive breast carcinoma of NST. The numbers of cases included in studies of 
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special types are often low. In clinical experience, some of the special types are recognized to 
have a good prognosis. However, the prognostic value of each histopathological type is not 
clarified. Lack of knowledge and documentation may lead to overestimation or 
underestimation of clinical value of prognostic markers. There is no doubt that 
histopathological grading is important in prognostication, but the findings in Paper III that 
ILC grade 2 has prognosis comparable to IDC grade 3 suggest that the significance of 
histopathological grade may differ in different histopathological types of breast cancer. The 
differing implications of histopathological grade in lobular and ductal carcinoma have also 
been demonstrated by others [223].  
In ILC, histopathological typing may be difficult, and in clinical pathology E-cad is a useful 
marker to distinguish lobular neoplasms from ductal. Distinguishing between these types has 
value because of the differences in prognosis. E-cad positive ILC has a survival comparable to 
that of IDC of the same grade regardless of E-cad status. Identification of E-cad negative ILC 
is probably of greater prognostic significance than detection of ILC per se. Since E-cad is 
already widely in use to identify ILC, this will not entail introduction of new methods. 
However, further studies, preferably on full-face sections, are required before implementation 
of E-cad as a prognostic marker in routine pathology.   
The study of TOP2A gave interesting and additional results. Previous research has been 
unable to clarify the prognostic and predictive value of TOP2A copy number change in breast 
cancer.  Changes in TOP2A copy number are infrequent, and when found, these changes were 
strongly associated with positive status for hormone receptor and for HER2. The study 
revealed that apparent differences in prognosis regarding TOP2A positive and negative status 
were hormone receptor and/or HER2-dependent. Thus, TOP2A copy number change had no 
independent prognostic value in this cohort of breast cancer patients. This study contributes to 
dispel TOP2A as a prognostic marker. However, the predictive value of TOP2A copy number 
change remains unresolved. 
 
8.2 Clinical benefit of molecular subtyping 
Consensus for molecular subtyping based on surrogate markers is still not established, but in 
order to compare, recent publications were used when the algorithm for subtyping (Figure 29) 
was created. Breast cancer is a complex group of diseases and complete understanding of this 
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complexity is missing. Gene expression analyses have taken the understanding of breast 
cancer further [118], but still the clinical benefit remains to be documented. A number of 
studies of molecular subtyping using IHC and ISH techniques as surrogates for gene 
expression analyses have been published [215, 216]. However, the best way to classify breast 
cancer is not settled. Further studies of known and novel markers may provide better and 
more precise classification. 
Gene profile studies are the background for molecular subtyping using surrogate markers. 
Some results from gene expression analyses are confirmed by studies based on IHC and ISH, 
but the different techniques do not necessarily provide the same information. In gene 
expression profiles, the number of mRNA molecules is counted as a measure of gene 
expression [92]. The proteins which are the functional units are not counted directly. 
Surrogate markers are easily available and can be applied to large cohorts. However, more 
studies are needed for both approaches and they are expected to be complementary in clinical 
practice [92]. Gene expression tests applicable on FFPE tissue are required. In new gene 
signature assays such as the PAM50, set of breast cancer related genes may be analysed in 
FFPE tissue thus enabling comparison between surrogate makers and gene signatures as 
predictors of survival [224, 225]. 
 
8.3 Cut-off controversies  
Lack of consensus applies to some of the biomarkers in these studies. Even the threshold for 
the well-established hormone receptor status is still to a certain extent controversial and the 
optimal cut off is not clarified [226]. ASCO/CAP recommends 1 % as cut off [126] and from 
St. Gallen the recommendation is to regard any staining as positive [127]. Deyarmin et al 
argue for classification of ER status into three groups: ER negative (< 1 %), low ER-staining 
(1 % - 10 %) and ER positive (≥ 10 %) [121]. Most low ER-stained tumours show gene 
profile compatible with the Luminal B or a non-luminal subtype [226]. The proportion of 
tumours with positive ER-staining in 1 % - 9 % of the cells is small [226]. In the present 
cohort there were 24 cases with positive ER-staining in 1 % - ≤ 9 % of the cells (unpublished 
data). Of these, 16 were Luminal B which had a poorer prognosis compared to Luminal A. 
Patients with low ER-staining tumours may benefit from both adjuvant endocrine treatment 
and chemotherapy [121, 226]. 
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Ki67 has been shown to have independent prognostic value in breast cancer [151]. St. Gallen 
recommended 14 % as cut off for Ki67 for distinguishing between Luminal A and Luminal B 
[227]. The evidence for this cut off is limited [228] and further studies are required. The 
agreement regarding Ki67 IHC measurement at both an interlaboratory and intralaboratory 
level is poor and assessment recommendations have been proposed [154]. Standardisation is 
still lacking and this is important to be aware of when comparing studies [228]. In this project, 
Ki67 < 15 % was defined as Ki67 low and Ki67 ≥ 15 % as Ki67 high. Ki67 was used to 
differentiate between Luminal A and Luminal B (HER2-) in accordance with St. Gallen [227]. 
All cases were assessed by two persons independently in order to improve the precision. 
However, we recognize the limitations of interpretation and the need for further research. 
 
8.4 Limitations of material and methods 
Fortunately, FFPE tumours have been archived and constitute valuable biobanks. The 
archives of Department of Pathology, St. Olav`s Hospital has made these studies possible. 
Still, attention to potential limitations is important. We have no control over the preanalytical 
conditions and the tissue may have been handled differently through time periods. However, 
in this project tissue quality was good irrespective of time period and IHC and ISH were 
successful in most cases. There was some loss of tissue, but the use of 3 cores per tumour in 
the TMAs minimized loss. Cases classified as 5NP may be false negative for one or more of 
the markers used in molecular subtyping. However, only seven of the 5NP cases showed no 
staining for any of the other markers used in these studies and only one case was not stained 
for any marker used in other studies in this project (unpublished data). This weighs in favour 
against false negative biomarker status.  
TMA technology has advantages and limitations discussed in the section 4.7 Tissue 
microarray. Transfer of the results from research using TMA to routine pathology cannot be 
done without further validation studies. In most institutions, assessment of IHC and ISH is 
done on full-face sections. It is necessary to ensure that the results from TMA studies are 
reproducible on full-face sections. This is important both when areas for TMA are selected 
according to specific criteria and when the areas are selected from random areas in the donor 
tissue. Cut-off levels for markers and their interpretation may differ and the results may, in the 
worst case, be invalid for full-face sections.  
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Two methods of visualization were used for ISH in this thesis. For HER2, a chromogen was 
used mainly because of the high number of cases on each slide (42 cases/slide) and the 
anticipation that the fluorescent signals might fade during analysis. Orientation in a TMA 
section when evaluating FISH is challenging. However, for an appreciable proportion of 
cases, the CISH signals were difficult to count and had to be classified as not possible to 
interpret. Consequently, for TOP2A in Paper II, FISH was chosen and assessment was done 
by two researchers one of whom counted the signals while the other recorded the results. In 
this way, signal fading was avoided.  
A number of studies are performed regarding amplification and co-amplification of TOP2A 
and HER2 in breast cancer and proportion of gene copy number changes for TOP2A varies. 
The proportion of TOP2A in the study in Paper II was lower than in comparable studies. In 
this study, a short DNA probe for TOP2A was used. Due to high frequency of co-
amplification with HER2, a long probe may because of overlap with HER2 result in a false 
high number of TOP2 [229].  
All three studies in this thesis are performed on the same historic population from Nord-
Trøndelag. The tumours are biopsied or removed over a wide span of time from the beginning 
of 1961 to the end of 2008 in 2 different hospitals. The TMAs are arranged according to time 
period and positive and negative controls have been implemented in all analyses to minimize 
misinterpretation. Some cases were excluded due to poor quality of the tissue. However, there 
was no clear association between time period and tissue quality.  
Few studies have been performed on archival tissue dating several decades back in time. One 
recent study, however, has shown that IHC can be applied successfully to specimens from as 
far back in time as the 1940s [230]. In that study, a rise in ER expression over time was found 
while PR and HER2 were stable. The difference in ER expression may be due to changes in 
routines and procedures in laboratories regarding fixation time. However, this does not 
explain the stability of PR and HER2 compared to ER. 
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9. Conclusions 
The conclusions in this thesis can be summarized as follows 
1. Histopathological grade: 
The main findings in this thesis are differences in survival for grade 2 tumours that can, to a 
great extent, be explained by differences in molecular subtypes. Statistically significant 
differences were demonstrated for grade 2 exclusively when comparing the molecular 
subtypes and when comparing ILC and IDC. The luminal subtypes had better prognosis 
compared to the non-luminal, and HER2 subtype and 5NP had poorest prognosis. Grade 2 
ILC had poorer prognosis compared to grade 2 IDC. This is important contribution in 
prognostication of the heterogeneous grade 2 tumours.  
2. Histopathological types: 
In the present project, statistical difference in survival for ILC and IDC of same 
histopathological grade is shown. Histopathological type may have independent value as a 
prognostic marker and the various biomarkers used in prognostication may have different 
impact for the different histopathological types.  
3. Prognostic markers 
Two well-known biomarkers which are not used in clinical routine as prognostic markers 
were studied in this project. Gene copy number changes in TOP2A had no independent value 
as prognostic marker in this historic cohort of women with breast cancer. This result applies 
both amplification and loss of TOP2A gene. Gene copy number changes in TOP2A are 
strongly associated with positive hormone receptor and HER2 status.  
E-cadherin is used as a diagnostic tool to distinguish lobular neoplasia, lobular carcinoma in 
situ and invasive lobular carcinoma from ductal carcinoma in situ and invasive carcinoma of 
no special type in difficult cases. In this cohort, E-cad negative ILC entailed a poorer 
prognosis compared to E-cad positive ILC. When not used in diagnostic pathology, E-
cadherin may prove useful as a prognostic marker in ILC. For IDC, E-cadherin had no 
prognostic value.  
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10. Future perspectives 
This thesis provides insight into the natural course of the disease in the various subtypes of 
breast cancer. This may have implications in further stratifying breast cancer patients for 
treatment. A substantial proportion of patients may be currently receiving adjuvant therapy 
unnecessarily. Some would probably not have experienced relapse even without adjuvant 
treatment and some fail to achieve sufficient effect. An important aim for future research is 
identification of the super survivors, patients who can avoid adjuvant treatment. This can be 
achieved through further development of the molecular subtyping based on surrogate markers. 
New application of well-known markers or implementation of novel markers is possible 
strategies. Furthermore, rapid developments in new technological approaches will enable us to 
carry out genetic analyses on archival tumour tissue. The results of the studies carried out in 
this project will be validated in further studies of other cohorts. E-cadherin may be useful in 
prognostication in ILC and validation studies on full-face sections are needed. 
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12. Errata 
 
Paper I: Two cases of mucinous carcinoma were interchanged regarding histopathological 
grade. One was histopathological grade 1 and the other was histopathological grade 3. This 
was corrected in Papers II and III.  
Paper I and II: One case was wrongly registered as HER2 negative.  This was corrected in 
Paper III.  
Paper I: In Table 2 the numbers of cases with < 5 lymph nodes examined are displaced with 
the number of lymph nodes not examined. This is corrected in Paper III. 
Paper II: In Table 3 the rows of numbers are displaced upwards in relation to the text in 
column 1.   
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Abstract Molecular subtyping of breast cancer may
provide additional prognostic information regarding patient
outcome. However, its clinical signiﬁcance remains to be
established. In this study, the main aims were to discover
whether reclassiﬁcation of breast cancer into molecular
subtypes provides more precise information regarding
outcome compared to conventional histopathological
grading and to study breast cancer-speciﬁc survival in the
different molecular subtypes. Cases of breast cancer
occurring in a cohort of women born between 1886 and
1928 with long-term follow-up were included in the study.
Tissue microarrays were constructed from archival for-
malin-ﬁxed, parafﬁn-embedded tissue from 909 cases.
Using immunohistochemistry and in situ hybridisation as
surrogates for gene expression analyses, all cases were
reclassiﬁed into the following molecular subtypes: Luminal
A; Luminal B (HER2-); Luminal B (HER2?); HER2
subtype; Basal phenotype; and ﬁve negative phenotype.
Kaplan–Meier survival curves and Cox proportional haz-
ards models were used in the analyses. During the ﬁrst
5 years after diagnosis, there were signiﬁcant differences in
prognosis according to molecular subtypes with the best
survival for the Luminal A subtype and the worst for HER2
and ﬁve negative phenotype. In this historic cohort of
women with breast cancer, differences in breast cancer-
speciﬁc survival according to subtype occur almost
exclusively amongst the histopathological grade 2 tumours.
From 5 years after time of diagnosis until the end of fol-
low-up, there appears to be no difference in survival
according to molecular subtype or histopathological grade.
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Abbreviations
BCSS Breast cancer-speciﬁc survival
BP Basal phenotype
CI Conﬁdence intervals
CISH Chromogenic in situ hybridization
CK5 Cytokeratin 5
EGFR Epithelial growth factor receptor 1
ER Oestrogen receptor
FFPE Formalin-ﬁxed, parafﬁn-embedded
GGI Gene expression grade index
HER2 Human epidermal growth factor receptor 2
HES Haematoxylin–erythrosin–saffron
HR Hazard ratio
IHC Immunohistochemistry/immunohistochemical
PR Progesterone receptor
5NP Five negative phenotype
SI Staining index
TMA Tissue microarray
Introduction
Breast cancer is the most common cancer and leading
cause of cancer-related death amongst women worldwide
[13, 35]. The disease is heterogeneous in its histopathol-
ogy, therapeutic response, metastatic patterns and outcome.
Current treatment guidelines are based on histopathological
grading, tumour size, lymph node-, hormone receptor-,
human epidermal growth factor receptor 2 (HER2)- and
proliferation (Ki67) status. More recently, gene expression
analyses using c-DNA microarray technology have pro-
vided a deeper understanding of the complexity of breast
cancer. Perou et al. [30] describe four molecular subtypes:
Luminal-like, HER2 enriched, Basal-like and Normal-like.
More recent publications have conﬁrmed these subtypes
with some modiﬁcations and it has been shown that
molecular subtypes also differ in their response to treat-
ment and outcome [4, 8]. Molecular subtyping with
immunohistochemistry (IHC) and in situ hybridisation
(ISH) as surrogates for gene expression analyses makes it
possible to study large numbers of archival breast cancer
cases with long-term follow-up.
Histopathological grade is a well-established prognostic
factor [3, 12, 32]. Recent studies conﬁrm the importance of
grading in breast cancer prognostication, although grading
systems based on gene expression, such as the Gene
expression grade index (GGI), have recently emerged [7,
32, 37]. Molecular subtyping may provide additional
information on patient outcome, but consensus has yet to
be reached regarding IHC or ISH markers that could be
used as surrogates for gene expression analyses [17]. Most
surrogate markers used for subtyping are available in
clinical practice today, but it remains to document the
beneﬁts of a new classiﬁcation prior to implementation.
The aims of this study were to discover whether
reclassiﬁcation of breast tumours into molecular subtypes
provides more information regarding outcome compared to
conventional histopathological grading and to study breast
cancer-speciﬁc survival (BCSS) for molecular subtypes
over time. To achieve this, a cohort of breast cancer cases
with long-term follow-up was reclassiﬁed into molecular
subtypes. Most of the markers examined are widely used,
such as oestrogen receptor (ER), progesterone receptor
(PR), HER2 and Ki67. In addition, cytokeratin 5 (CK5) and
epithelial growth factor receptor 1 (EGFR) were included
[2, 6]. The patients in this population experienced breast
cancer in a time period or at an age where adjuvant treat-
ment after surgery was rarely an option and the disease thus
had a near-natural course.
Materials and methods
Study population
Between 1956 and 1959, 25,897 women in the Norwegian
county of Nord-Trøndelag, born between 1886 and 1928,
were invited to participate in a screening programme for
early diagnosis of breast cancer [22, 29]. The screening
comprised a clinical examination and a questionnaire
focussed on reproductive history. Data were linked with the
Norwegian Cancer Registry and the Cause of Death Reg-
istry of Norway. In all, 1,393 new cases of breast cancer
occurred between 1961 and 2008. Most of these were
analysed at the Department of Pathology, St. Olav’s Hos-
pital, Trondheim University Hospital, Norway. A total of
448 cases were excluded from the study. For the remaining
945 cases, formalin-ﬁxed, parafﬁn-embedded (FFPE) tis-
sue was available and 909 were of sufﬁcient quality for
reclassiﬁcation into molecular subtypes (see Fig. 1).
Specimen characteristics
Pathology reports and FFPE tissue from all cases were
retrieved from the archives of the department of pathology.
In cases with recurrent disease or second or multiple pri-
mary breast cancer, only the ﬁrst primary tumour was
included. New 4-lm-thick full-face sections were cut from
representative parafﬁn blocks from tumours and lymph
node metastases and stained with haematoxylin–erythro-
sine–saffron (HES). Forty cases comprised only core
biopsies or small tissue fragments unsuitable for tissue
microarray (TMA). From these, serial sections were made.
The HES-stained sections were reviewed under a
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microscope independently by two experienced pathologists
(OAH, AMB) and classiﬁed according to histopathological
type and grade according to the World Health Organization
Classiﬁcation of Tumours [23] and the Nottingham grading
system [12, 33]. Any discrepancies in grade or type were
discussed and consensus reached. In cases where tumour
size was missing in the pathology report, size was mea-
sured in millimetres on the glass slide. Only cases with a
measurement of the whole tumour in the pathology report
and/or measurement of the full diameter on the glass slide
were registered. All other cases were classiﬁed as size
uncertain [n = 268 (29.5 %)].
TMA construction
TMA blocks were made using the Tissue Arrayer Mini-
Core 3 with TMA Designer2 software (Alphelys). Areas
of interest in the HES sections were marked by a pathol-
ogist. Three 1-mm-diameter tissue cores were extracted
from peripheral regions of the tumour in the FFPE blocks
and inserted into TMA recipient blocks. From the TMA
blocks, 4-lm sections were cut and stained. IHC was done
with antibodies for ER, PR, HER2(CB11), CK5, Ki67 and
EGFR in addition to HES staining. In addition, HER2
status was also examined by chromogenic in situ hybrid-
ization (CISH).
Assay methods
Sections were mounted on Superfrost?glass slides, dried at
37 C overnight and stored at -20 C. All sections were
stained within 12 weeks of sectioning. The slides were
heated to 60 C for 2 h. Pre-treatment was performed in a PT
Link, Pre-Treatment Module for Tissue Specimens (Dako)
with buffer (High pH Target Retrieval Solution K8004) at
97 C for 20 min. All sections were immunostained for ER,
PR, HER2 (CB11), CK5 and Ki67 in a DakoCytomation
Autostainer Plus (Dako). For visualization, the Dako
REALTM EnVisionTM Detection System was used with
Peroxidase/DAB?, Rabbit/Mouse, code K5007. EGFR was
immunostained using EGFR pharmDxTM for autostainer,
code K1494. See Table 1 for sources and dilutions of pri-
mary antibodies. Negative controls were included in each
staining run. CISHwas used to visualize theHER2 gene (red
chromagen) and chromosome 17 (blue chromagen) using the
dual colour probe kit HER2 CISH pharmDxTMKit, code 109
(Dako). Two of the steps in the CISH procedure were mod-
iﬁed slightly. The incubation time for red chromogen solu-
tion was increased from 10 to 15 min, and the dilution of
haematoxylin was increased from 1:5 to 1:7.
Scoring and reporting
All HES- and IHC-stained slides were digitalized using the
tissue scanner AriolTM SL-50 3.3 Scan system and analysis
station (Genetix) at 59 and 209 magniﬁcation. Expression
of ER, PR, HER2 (CB11), CK5, Ki67 and EGFR was
evaluated using the Ariol review station. The images were
viewed and subjectively scored by two persons indepen-
dently. HER2 gene ampliﬁcation status was annotated
under a bright ﬁeld microscope. All cases were evaluated
by at least one pathologist. Any discrepancies were dis-
cussed and consensus reached.
Classiﬁcation of each marker
ER and PR were positive when C1 % of the tumour cells
showed positive nuclear staining [19]. For Ki67, a total of
500 tumour nuclei were examined. Cases with C15 %
positive nuclei were classiﬁed as Ki67 high and\15 % as
Ki67 low [16].
HER2 was assessed using both IHC and CISH [11]. For
HER2 IHC, the CB11 clone [31, 43] was used and the
Herceptest (Dako) guidelines for interpretation were used
with a membrane-staining score ranging from 0 to ?3.
Fig. 1 Study population
Table 1 Sources and dilutions of primary antibodies
Antibody Clone Manufacturer Concentration
of antibody
Dilution
ER SP1 Cell marque 33 mg/ml 1:100
PR 16 Novocastra 360 mg/l 1:400
HER2 CB11 Novocastra 3.9 g/l 1:640
Ki67 MIB1 Dako 35 mg/l 1:100
CK5 XM26 Novocastra 50 mg/l 1:100
EGFR 2-18C9 Dako Ready to use No dilution
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HER2 IHC was considered negative when the score was 0
or ?1, positive when ?3 and borderline when ?2. Since
the preanalytical treatment of the samples was unknown,
the results of HER2 IHC were only used in cases where
CISH was unsuccessful. In IHC (?2) and unsuccessful
CISH (18 cases), the corresponding IHC was revised by
two authors (AMB and MJE) and reclassiﬁed as either
?1(14 cases) or ?3(4 cases).
The HER2 gene was considered ampliﬁed if the gene to
chromosome ratio was C2.0 [1, 34]. A minimum of 20
non-overlapping nuclei with signals for both chromosome
and gene were assessed.
For CK5, a staining index (SI) was estimated. Staining
intensity was graded as 0 (no staining), 1 (weak), 2
(moderate) and 3 (strong). The proportion of positive
staining cells was scored as 1 (\10 %), 2 (10–50 %) and 3
([50 %). The score for intensity multiplied by proportion
is the SI [14, 26]. In this study, the results were considered
to be negative when SI was 0–1 and positive when the SI
was 2–9. For EGFR, membranous staining was scored
according to the guidelines in the Dako PharmDx kit and a
SI was calculated when this was combined with the pro-
portion of cells showing positive staining resulting in a SI
as described above.
Classiﬁcation of molecular subtypes
Using the six biomarkers, the tumours were then classiﬁed
in molecular subtypes: Luminal A, Luminal B (HER2-),
Luminal B (HER2?), HER2 subtype ﬁve negative phe-
notype (5NP) and Basal-like phenotype (BP) (Fig. 2).
Statistical analyses
All women were followed from the date of breast cancer
diagnosis to the date of death from breast cancer, death
from any other cause or to the end of follow-up (December
31, 2010), whichever came ﬁrst. BCSS according to
molecular subtypes and histopathological grade was esti-
mated using Kaplan–Meier methods and compared by log-
rank tests. Cox proportional hazards models were used to
estimate risk of death from breast cancer adjusted for age
(5-year intervals), stage (in ﬁve categories: stage I–IV and
unknown) at diagnosis according the data from the Cancer
Registry [21] and time period of diagnosis (10-year inter-
vals). Hazard ratios (HR) were calculated with 95 % con-
ﬁdence intervals (CI) for two time periods: ﬁrst 5 years
after diagnosis and from 5 years after diagnosis and
onwards (conditional on surviving the ﬁrst 5 years). Cox
analyses of the ﬁrst 5 years were stratiﬁed by histopa-
thological grade. Statistical analyses were carried out using
Stata version 12.1 IC for Windows (Stata Corp.). This
study complies with the REMARK reporting recommen-
dations for tumour marker studies [25].
Ethics
The study was approved by the Regional Committee for
Medical and Health Sciences Research Ethics (REK, Midt-
Norge, ref. nr: 836/2009) and dispensation from the
requirement of patient consent was granted.
Results
Description of the population
In all, 909 cases were included. Mean age at diagnosis was
72.5 years (SD 10.7; range 41–102). Only 12.5 %
were\60 years and 58.9 % were 60–79 years. Most
tumours were 2–5 cm in diameter (43.2 %), but for
29.5 %, tumour size was unknown or uncertain. At the end
of the observation period, 359 (39.5 %) had died of breast
cancer, 390 (42.9 %) of other causes and 160 (17.6 %)
Fig. 2 Classiﬁcation algorithm
for molecular subtyping
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were still alive. Median follow-up was 6.4 years [inter-
quartile range (IQR) 10.0 years]. See Table 2 for patient
and tumour data.
Histopathological characteristics
Of the 909 tumours, 12.9 % were grade 1, 53.7 % grade 2
and 33.4 % grade 3. The histopathological types were as
follows: ductal: 70.0 %; lobular: 13.6 %; and other special
types: 16.4 %. All cases were reclassiﬁed into molecular
subtypes based on assessment of ER, PR, HER2, Ki67, CK5
and EGFR. Table 2 shows distribution of histopathological
types and grades for each molecular subtype. Table 3 shows
the number of positive cases of each marker.
Distribution of molecular subtypes
The distribution of subtypes was as follows: Luminal A:
47.6 %; Luminal B (HER2-): 27.4 %; Luminal B
(HER2?): 7.7 %; HER2 subtype: 6.6 %; 5NP: 3.6 %; and
Table 2 Descriptive statistics for the 909 breast cancer cases
Luminal
A
Luminal B
(HER2-)
Luminal B
(HER2?)
HER2
type
5 Negative
phenotype
Basal
phenotype
Total
Number (%) 433 (47.6) 249 (27.4) 70 (7.7) 60 (6.6) 33 (3.6) 64 (7) 909
Mean age at diagnosis (SD) 73.9 (9.9) 71.9 (10.9) 69 (11.4) 67.3 (11.6) 75.9 (11.1) 71.7 (11.3) 72.5 (10.7)
Median years of follow-up after
diagnosis (IQR)
7.4 (9.3) 7.0 (11.1) 5.2 (12.5) 3.2 (8.1) 3.4 (8.5) 5.1 (9.1) 6.4 (10.0)
Tumour grade (%)
1 91 (21.0) 20 (8.0) 2 (2.9) 0 0 4 (6.3) 117 (12.9)
2 297 (68.6) 120 (48.2) 33 (47.1) 10 (16.7) 21 (63.6) 7 (10.9) 488 (53.7)
3 45 (10.4) 109 (43.8) 35 (50.0) 50 (83.3) 12 (36.4) 53 (82.8) 304 (33.4)
Histopathological type (%)
Ductal 299 (69.1) 182 (73.1) 57 (81.4) 47 (78.3) 14 (42.4) 37 (57.8) 636 (70.0)
Lobular 68 (15.7) 35 (14.1) 6 (8.6) 1 (1.7) 12 (36.4) 2 (3.1) 124 (13.6)
Tubular 4 (0.9) 0 0 0 0 0 4 (0,4)
Mucinous 31 (7.2) 8 (3.2) 3 (4.3) 0 0 1 (1.6) 43 (4.7)
Papillary 19 (4.4) 7 (2.8) 3 (4.3) 1 (1.7) 0 2 (3.1) 32 (3.5)
Medullary 0 6 (2.4) 0 6 (10.0) 2 (6.1) 7 (10.9) 21 (2.3)
Metaplastic 0 1 (0.4) 0 2 (3.3) 1 (3.0) 9 (14.1) 13 (1.4)
Other 12 (2.8) 10 (4.0) 1 (1.4) 3 (5.0) 4 (12.1) 6 (9.4) 36 (4.0)
Tumour sizea (%)
\2 94 (21.7) 50 (20.1) 12 (17.1) 4 (6.7) 3 (9.1) 6 (9.4) 169 (18.6)
2–5 193 (44.6) 97 (39.0) 27 (38.6) 21 (35.0) 18 (54.5) 37 (57.8) 393 (43.2)
[5 35 (8.1) 19 (7.6) 7 (10.0) 13 (21.7) 2 (6.1) 3 (4.7) 79 (8.7)
Uncertain 111 (25.6) 83 (33.3) 24 (34.3) 22 (36.7) 10 (30.3) 18 (28.1) 268 (29.5)
Lymph node invasiona
Yes 129 (29.8) 82 (32.9) 25 (35.7) 32 (53.3) 15 (45.5) 27 (42.2) 310 (34.1)
No (C5 nodes or SNBb) 142 (32.8) 66 (26.5) 24 (34.3) 15 (25.0) 5 (15.2) 21 (32.8) 273 (30.0)
No (\5 nodes examined) 123 (28.4) 84 (33.7) 20 (28.6) 9 (15.0) 10 (30.3) 11 (17.2) 257 (28.3)
Uncertain 39 (9.0) 17 (6.8) 1 (1.4) 4 (6.7) 3 (9.1) 5 (7.8) 69 (7.6)
Stagec
I 238 (55.0) 123 (49.4) 29 (41.4) 23 (38.3) 15 (45.5) 27 (42.2) 455 (50.1)
II 157 (36.3) 90 (36.1) 28 (40.0) 27 (45.0) 14 (42.4) 30 (46.9) 346 (38.1)
III 23 (5.3) 17 (6.8) 3 (4.3) 7 (11.7) 3 (9.1) 4 (6.3) 57 (6.3)
IV 13 (3.0) 17 (6.8) 8 (11.4) 3 (5.0) 1 (3.0) 3 (4.7) 45 (5.0)
Unknown 2 (0.5) 2 (0.8) 2 (2.9) 0 0 0 6 (0.7)
a Histologically conﬁrmed
b Sentinel node biopsy
c Cancer Registry of Norway, combined clinical and histological stage
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BP: 7.0 %. See Table 2. Mean age at diagnosis was 72.8
(SD 10.5) for women with luminal tumours and 70.9 (SD
11.8) for non-luminal tumours. Luminal A had the highest
proportion of grades 1 and 2 (Fig. 3). Only HER2 subtype
and BP comprised a higher proportion of grade 3
than grade 2. Grade 1 was not found in HER2 and 5NP
subtypes. The Luminal B subtypes had very similar
distribution of grades despite differences in other
characteristics.
Breast cancer-speciﬁc survival, molecular subtypes
and histopathological grade
Luminal A subtype had the best survival, closely followed
by Luminal B (HER2-) with 5-year BCSS higher than
75 %. The HER2 and 5NP subtypes had the poorest
prognosis, with 5-year survival around 50 %. Of the triple-
negative cases, BP had a better prognosis than 5NP. BP and
Luminal B (HER2?) were similar in terms of 5-year sur-
vival (Fig. 4).
Figure 5 shows BCSS according to histopathological
grade for up to 20 years of follow-up. Adjustment for age
did not substantially inﬂuence the curves, but after
adjustment for stage, survival for grade 1 tumours was
improved (data not shown).
Risk of death from breast cancer
Table 4 shows risk of death from breast cancer according
to molecular subtype and histopathological grade. During
the ﬁrst 5 years, grades 2 and 3 had a poorer prognosis
compared to grade 1 with HR 3.8 (95 % CI 2.14–6.75) for
grade 3 and HR 1.97 (95 % CI 1.11–3.51) for grade 2. In
the same time period, the hormone receptor-negative and/
or HER2-positive subtypes had the poorest prognoses
compared to Luminal A. Particularly poor prognoses were
shown for the HER2 subtype [HR 4.24 (95 % CI
2.79–6.42)] and 5NP [HR 3.34, (95 % CI 1.91–5.82)].
After 5 years, neither grade nor molecular subtype showed
any clear association with survival. Adjustment for age had
no impact on the results, and adjustment for stage only
slightly attenuated risk estimates.
Table 5 shows risk of death from breast cancer the ﬁrst
5 years after diagnosis according to molecular subtype for
grade 2 and 3. For grade 2, the HR for HER2 subtype
compared to Luminal A was 6.62 (95 % CI 2.82–15.57),
and adjustment for age and stage did not substantially
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Table 3 The number of positive cases for each marker
Marker No. of positive (%) Not possible to interpret
ER 749 (82.4) 2 (0.2 %)
PR 521 (57.3) 1 (0.1 %)
HER2 130 (14.3) 0
Ki67 406 (44.7) 1 (0.1 %)
CK5 164 (18.0) 0
EGFR 64 (7.0) 0
0
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Fig. 3 Distribution of grade in percent according to subtype
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inﬂuence the estimate. In grade 3, there was no clear dif-
ference in risk of death from breast cancer according to
molecular subtype. Since 12 of the 13 patients who died of
grade 1 tumours had Luminal A tumours, HRs were not
calculated. Adjustment for time period of diagnosis did not
change the results (not shown).
Amongst HER2-positive cases, the hazard ratio for the
HER2 subtype compared to Luminal B (HER2?) was 1.8
(95 % CI 1.07–3.05) (not shown in table).
Discussion
In this long-term follow-up of breast cancer patients, the
HER2 and 5NP subtypes showed the poorest prognosis
during the ﬁrst 5 years after diagnosis. After 5 years, BCSS
did not signiﬁcantly differ amongst the six molecular
subtypes. However, the numbers of 5-year survivors in
these two groups are low. The patients came from a cohort
of women with breast cancer who lived through a time
period with limited access to adjuvant treatment. However,
192 women would have qualiﬁed for antihormonal treat-
ment according to the treatment guidelines operative at the
time of diagnosis. None were qualiﬁed for treatment with
trastuzumab. Kaplan–Meier BCSS estimates for patients
with ER-positive tumours who may have received treat-
ment and those who did not qualify for treatment do not
differ signiﬁcantly (data not shown).
During the ﬁrst 5 years of follow-up, differences in
survival according to subtype occurred almost exclusively
amongst patients with grade 2 tumours. Grade 2 was sig-
niﬁcantly associated with poorer survival for all subtypes
except Luminal B (HER2-).
These results support the ﬁndings of others that hormone
receptor status deﬁnes two groups within HER2-positive
breast cancer with differing BCSS [42]. The HER2 subtype
had the poorest 5-year survival of all subtypes, whereas the
Luminal B (HER2?) subgroup had a substantially better
Table 4 Risk of death from breast cancer according to molecular subtype and histopathological grade
No. of cases Deaths from breast cancer HR 95 % CI
unadjusted
HR 95 % CI
adjusted for age
HR 95 % CI
adjusted for stage
Histopathological grade, follow-up ﬁrst 5 years after diagnosis
1 117 13 1.00 1.00 1.00
2 488 101 1.97 1.11–3.51 1.95 1.09–3.48 1.47 0.82–2.64
3 304 110 3.80 2.14–6.75 3.74 2.10–6.66 3.12 1.75–5.55
909 224
Histopathological grade, follow-up from 5 years after diagnosisa
1 78 18 1.00 1.00 1.00
2 291 83 1.37 0.82–2.29 1.29 0.77–2.16 1.21 0.72–2.02
3 153 34 0.98 0.55–1.74 0.94 0.53–1.67 0.90 0.51–1.60
522 135
Molecular subtype, follow-up ﬁrst 5 years after diagnosis
Luminal A 433 73 1.00 1.00 1.00
Luminal B (HER2-) 249 56 1.42 1.01–2.02 1.42 1.00–2.02 1.29 0.92–1.84
Luminal B (HER2?) 70 25 2.33 1.48–3.67 2.36 1.48–3.74 2.11 1.33–3.33
HER2 60 32 4.24 2.79–6.42 4.39 2.86–6.72 3.72 2.44–5.65
5 Negative phenotype 33 15 3.34 1.91–5.82 3.18 1.81–5.61 3.17 1.81–5.53
Basal phenotype 64 23 2.43 1.52–3.89 2.38 1.48–3.82 2.39 1.48–3.82
909 224
Molecular subtype, follow-up from 5 years after diagnosisa
Luminal A 271 69 1.00 1.00 1.00
Luminal B (HER2-) 148 44 1.15 0.79–1.68 1.21 0.82–1.77 1.15 0.80–1.69
Luminal B (HER2?) 36 10 0.81 0.41–1.57 0.88 0.44–1.73 0.92 0.46–1.83
HER2 23 4 0.66 0.24–1.80 0.71 0.26–1.96 0.66 0.24–1.82
5 Negative phenotype 12 3 0.84 0.27–2.68 0.89 0.27–2.90 0.94 0.30–3.01
Basal phenotype 32 5 0.58 0.23–1.43 0.62 0.25–1.55 0.58 0.23–1.46
522 135
HR hazard ratio, CI conﬁdence interval
a Conditional on surviving the ﬁrst 5 years
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5-year survival, supporting the signiﬁcance of ER status in
determining survival. It has been shown that, despite
problems associated with crosstalk between ER and HER2,
Luminal B (HER2?) beneﬁts from antihormonal treatment
[20]. The hazard ratio for the HER2 subtype compared to
Luminal B (HER2?) would appear to conﬁrm this.
To predict response to endocrine therapy, the cutoff for
ER was previously set at 10 % positive staining nuclei
[28]. In accordance with current guidelines, the cutoff is
now set at C1 % [19]. In this study, 24 cases showed ER-
positive staining in C 1\ 10 % of tumour cell nuclei and
were classiﬁed as Luminal. A majority (16 cases) were
Luminal B, and in the Luminal B (HER2?) subtype, they
accounted for 9 % of cases. Deyarmin et al. [10] have
suggested that the classiﬁcation of ER-low tumours as
Luminal may be inappropriate. These cases exert little or
no inﬂuence on the results of the Kaplan–Meier and Cox
analyses in the present study.
Classiﬁcation of breast cancer into molecular subtypes
with surrogate markers for gene expression is widely used.
In 2010, Blows et al. [4] published a large collaborative
analysis that showed survival for different subtypes, where
the subtyping in all the 12 included studies was done by
IHC. These methods are more accessible and affordable
than gene proﬁle studies and can be applied to archival
FFPE tissue. The St. Gallen Consensus Discussion in 2011
opened for molecular subtyping of breast cancer using ER,
PR, HER2 and Ki67/grade, all factors already in clinical
use, though the cutoff for Ki67 is still controversial [18].
The panel did not support the incorporation of EGFR or
CK 5/6, thus the basal phenotype and the ﬁve negative
phenotype were classiﬁed as ‘triple negative’ [15, 17].
Discussion is ongoing regarding which markers are best
suited for the classiﬁcation of molecular subtypes.
In the present study, 5-year survival was better for BP
compared to 5NP. This is in contrast with the ﬁndings of
others [4, 6, 40]. The 5NP subtype had poorer prognosis
despite the fact that it comprised a higher proportion of
histological grade 2 tumours. Validation studies will reveal
whether or not this ﬁnding is consistent. This may be a
group that would have beneﬁted from adjuvant treatment as
offered today.
Histopathological grade, tumour size and lymph node
status are strong prognostic factors and are well established
in clinical practice. Reduced long-term survival is associ-
ated with higher grade [4, 36, 44]. In the present study,
high grade was associated with non-luminal subtypes.
However, the prognostic value of the different factors may
vary with time after diagnosis [24]. Since the risk of
relapse and death is the highest during the ﬁrst 5 years,
particularly for ER-negative disease [27, 41], two periods
of time were analysed separately in this study: the ﬁrst
5 years after diagnosis and the subsequent years. Even after
many years, there is some risk of breast cancer recurrence.
Interestingly, in this cohort, there are no differences in
survival according to subtypes for those who have survived
the ﬁrst 5 years. Further research may reveal whether
adjuvant treatment modiﬁes this tendency.
Table 5 Risk of death from breast cancer according to molecular subtype for each histopathological grade
Number of cases Deaths from breast cancer HR 95 % CI
Unadjusted
HR 95 % CI
Adjusted for age
HR 95 % CI
Adjusted for stage
Molecular subtype, follow-up ﬁrst 5 years after diagnosis: grade 2
Luminal A 297 45 1.00 1.00 1.00
Luminal B (HER2-) 120 24 1.45 0.88–2.38 1.50 0.91–2.48 1.33 0.81–2.19
Luminal B (HER2?) 33 12 2.67 1.41–5.04 2.97 1.54–5.70 2.29 1.20–4.38
HER2 10 6 6.62 2.82–15.57 7.81 3.18–19.18 5.64 2.36–13.51
5 Negative Phenotype 21 11 4.68 2.42–9.06 3.91 1.97–7.76 4.42 2.26–8.64
Basal Phenotype 7 3 3.39 1.05–10.92 2.56 0.75–8.69 3.35 1.03–10.85
488 101
Molecular subtype, follow-up ﬁrst 5 years after diagnosis: grade 3
Luminal A 45 16 1.00 1.00 1.00
Luminal B (HER2–) 109 31 0.73 0.40–1.34 0.73 0.39–1.36 0.57 0.31–1.04
Luminal B (HER2?) 35 13 1.00 0.48–2.09 0.96 0.45–2.05 0.85 0.41–1.79
HER2 50 26 1.60 0.86–2.99 1.60 0.84–3.05 1.21 0.64–2.29
5 Negative Phenotype 12 4 0.90 0.30–2.70 0.87 0.28–2.64 0.94 0.31–2.82
Basal Phenotype 53 20 1.07 0.55–2.06 1.07 0.54–2.11 0.86 0.44–1.68
304 110
Follow-up ﬁrst 5 years after diagnosis. HRs were not calculated for histopathological grade 1 because 12 of the 13 patients who died of grade 1
tumour had Luminal A tumour
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Histopathological grade 1 tumours are associated with
the best prognosis, whereas grade 3 tumours are associated
with the poorest prognosis. Grade 2 tumours comprise a
more heterogeneous group where the majority has an
intermediate prognosis, but some cases may exhibit simi-
larity with grades 1 and 3 [7, 32]. The same applies in this
study. It is possible to classify grade 2 tumours into low
risk and high risk of recurrence using the GGI which is
based on analysis of 97 genes [37]. A 3-gene proliferation
score using PCR assay to identify TOP2A, FOXM1 and
MKI67 has similar prognostic value as GGI and might be
easier to implement [39]. However, the present study
shows that it is possible to obtain signiﬁcant additional
information of prognostic value by using already imple-
mented or readily accessible tests, and this may be of value
in prognostication of grade 2 tumours.
This study contributes to the understanding of breast cancer
heterogeneity partly because of the unique nature of the study
population. These women lived in a time before birth control
pills and hormone replacement therapy at menopause were
available, and they had not undergone organized mammog-
raphy screening. Furthermore, due to age and time period,
they had limited postoperative treatment and thus we come as
close to the natural course of the disease as possible. One
drawback in this study is the relatively high age of the cohort
and the results must be considered in light of this fact. This
may explain the relatively high proportion of grade 2 tumours
and the slightly lower proportion of HER2-positive tumours
[38]. Another weakness may be the IHC estimation of HER2
where standardized preanalytical conditions were unattain-
able, thus precluding a semiquantitative estimation of protein
expression. Despite this, there was full correlation between
IHC and CISH in 587 cases. 13 cases were IHC ? 3, but
showed chromosome 17 polysomy with ratios\2.0. Two
cases scored?3, but no changes in chromosome or gene copy
number. For the same reason, false-positive and -negative
results may have occurred for the other biomarkers. However,
the distribution of subtypes is comparable to that of other
studies [4, 5, 9]. All laboratory tests were carried out under
standardized conditions and their interpretation together with
complete revision of the histopathological diagnoses, type and
grade was done within the context of this study according to
present-day guidelines. By adding twomarkers to identify the
basal phenotype to the set of markers in clinical use, it was
possible to subdivide triple-negative cases into BP and the
5NP. In this study, these two subtypes had signiﬁcantly dif-
fering BCSS. Molecular tests such as GGI are promising in
terms of clinical beneﬁt, but so far the documented beneﬁt is
complementary to histopathological methods [32]. Similarly,
molecular subtyping using surrogate markers may provide
important additional information for selected subgroups of
breast cancer patients.
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ABSTRACT
Aims The clinical signiﬁcance of TOP2A as a prognostic
marker has not been clariﬁed. The aims of this study
were to investigate the frequency of TOP2A copy number
change; to correlate TOP2A with HER2 status, hormone
receptor (HR) status and molecular subtype, and further
to explore differences in breast cancer-speciﬁc survival
according to TOP2A and HER2.
Methods In this study, TOP2A, HER2 and chromosome
17 copy number were assessed in 670 cases of breast
cancer using in situ hybridisation techniques. Gene to
chromosome ratios ≥2 were classiﬁed as ampliﬁcation.
TOP2A deletion (gene to chromosome ratio ≤0.8) or
monosomy (only one signal for both gene and chromosome
in more than 75% of nuclei) were classiﬁed as gene loss.
Results A strong association between TOP2A change and
HR and HER2 status was found. During the ﬁrst 5 years after
diagnosis, the risk of death from breast cancer was
signiﬁcantly higher for cases with HER2 ampliﬁcation
irrespective of TOP2A status.
Conclusions TOP2A copy number change was strongly
associated with HR and HER2 status and as a prognostic
marker TOP2A is probably of limited value.
INTRODUCTION
The HER2 gene has a well-established biological
and clinical role in breast cancer, and the HER2
amplicon on chromosome 17 harbours a number
of genes involved in breast cancer pathophysiology.
Copy number change among these genes is fre-
quently observed though their signiﬁcance remains
to be clariﬁed.1
TOP2A is one of the genes close to HER2 and its
protein product, topoisomerase II α, is the molecular
target of anthracycline treatment. TOP2A ampliﬁca-
tion status has been thought to be linked to response
to treatment. However, data are conﬂicting and, as
yet, unresolved.2 HER2 and TOP2A are associated
with high histopathological grade3 and high prolifer-
ation,4 but the clinical signiﬁcance of TOP2A and its
relationship toHER2 have not been clariﬁed.
The aims of this study were to investigate the fre-
quency of TOP2A copy number change in a well-
characterised cohort of women with breast cancer5
and to correlate TOP2A with HER2 status,
hormone receptor (HR) status and molecular
subtype. A further objective was to explore differ-
ences in breast cancer-speciﬁc survival (BCSS)
according to TOP2A and HER2.
MATERIALS AND METHODS
Study population
A screening programme for early diagnosis of breast
cancer was conducted by the Norwegian Cancer
Registry between 1956 and 1959. The patients devel-
oped breast cancer in a time period with limited access
to adjuvant treatment. None were treated with anthra-
cyclines or trastuzumab. According to the guidelines at
the time of diagnosis, 30.7% patients may have quali-
ﬁed for treatment with tamoxifen. The population has
been described in detail previously.5–7 A total of 1393
women in the underlying population developed breast
cancer in the follow-up period from 1961 to the end
of 2008. Of these, 945 had tissue samples available at
the Department of Pathology and Medical Genetics,
St. Olav’s Hospital, Trondheim, Norway, and 670
were suitable for assessment of TOP2A and HER2
copy number. Survival data were generated after
linkage between the Cause of Death Registry of
Norway and the Norwegian Cancer Registry.
Specimen characteristics
All cases in this study have previously been classi-
ﬁed according to histopathological type and grade
and reclassiﬁed in molecular subtypes according to
ﬁgure 15 using oestrogen receptor (ER),
Figure 1 Classiﬁcation algorithm for molecular subtyping.
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progesterone receptor (PR), Ki67, cytokeratin 5 and epithelial
growth factor receptor (EGFR) 1 as surrogate markers for gene
expression. HER2 status was assessed using chromogenic in situ
hybridisation (CISH).
Assay methods
For the present study, ﬂuorescence in situ hybridisation (FISH)
was employed for detection of TOP2A and chromosome 17
according to the manufacturer`s guidelines. Pretreatment was
done using Histology FISH Accessory Kit, code K5799 (Dako).
The probe mix (VYSIS TOP2A/CEP 17 FISH Probe Kit, code
03N89-020 Abbott Molecular Inc) was applied and denatured
at 73°C for 5 min before hybridisation at 37°C overnight. For
HER2 and chromosome 17, the HER2 CISH pharmDx Kit,
code 109 (Dako), was used and immunostaining for ER (ER
SP1 Cell Marqque 33 mg/mL 1:100) and PR (PR 16 Novocastra
360 mg/mL 1:400) was done in a DakoCytomation Autostainer
Plus (Dako) using Dako REAL EnVision Detection System with
Peroxidase/DAB+, Rabbit/Mouse, code K5007, as previously
described.5
Scoring and reporting
TOP2A gene copy number was evaluated under a ﬂuorescence
microscope (Nikon Eclipse 90i) and HER2 gene under a bright
ﬁeld microscope (Nikon Eclipse 80i) by three of the authors
(AMB, BY and MJE). A minimum of 20 non-overlapping
tumour cell nuclei with signals for both chromosome and gene
were counted in each case. Gene to chromosome ratios ≥2 were
classiﬁed as ampliﬁcation.8–11 TOP2A was considered to be
deleted when the gene to chromosome ratio was ≤0.8.9 12
Cases with only one signal for both gene and chromosome in
more than 75% of all nuclei were recorded as monosomy. In
the analyses, deletion and monosomy were grouped together.
ER and PR were classiﬁed as positive when ≥1% of the tumour
cells showed positive nuclear staining.
Statistical analyses
Follow-up was from breast cancer diagnosis to death from breast
cancer, death from any other cause or to December 31, 2010,
whichever occurred ﬁrst. BCSS was estimated using the Kaplan–
Meier method, and Cox proportional hazards models were used
to estimate risk of death from breast cancer. HRs were calcu-
lated with 95% CIs using Stata V.12.1 IC for Windows (Stata
Corp).
RESULTS
Description of breast cancer cases
Of the 670 cases, 251 (37.5%) died of breast cancer, 314
(46.9%) died of other causes, and at the end of the observation
period, 105 (15.6%) were still alive. Mean age at diagnosis was
73.1 years (SD 9.8; range 41–96 years), and median follow-up
was 6.6 years (IQR 9.42 years). Histopathological grade,
tumour size and molecular subtypes are given in table 1.
Ampliﬁcation and deletion
Table 2 shows ampliﬁcation of TOP2A was found in 41 cases
(6.1%) and monosomy or deletion in 25 (3.7%). HER2 was
ampliﬁed in 110 cases (16.4%) and co-ampliﬁed with TOP2A in
32 cases (4.8%). Of the 25 cases with TOP2A loss, 6 were amp-
liﬁed for HER2. The majority with TOP2A ampliﬁcation
(78.1%) were co-ampliﬁed with HER2, whereas 34.5% of the
HER2 ampliﬁed tumours were either TOP2A ampliﬁed or
showed TOP2A loss. The proportion of HR+ tumours was
higher among cases with TOP2A ampliﬁcation (75.6%) and
TOP2A loss (68.0%) compared with HER2 ampliﬁcation
(55.5%).
Ampliﬁcation and loss according to molecular subtypes
With the exception of 5NP, TOP2A copy number aberrations
were found in all subtypes and were associated with both HR
and HER2 status. A majority of 56.1% of TOP2A ampliﬁed
cases were Luminal B (HER2+). Loss of TOP2A was found
among the HR+ and HER2 negative subtypes (Luminal A and
Luminal B (HER2−)) (64.0%) or HER2 subtype (20.0%). One
of four TOP2A deleted case was Luminal B (HER2+).
BCSS, TOP2A and HER2
The Kaplan–Meier plots in ﬁgures 2 and 3 show BCSS accord-
ing to TOP2A and HER2, respectively, and in ﬁgure 4 the BCSS
according to the status of both genes. Loss of TOP2A in the
absence of HER2 ampliﬁcation did not affect BCSS. The
Kaplan–Meier plots show poorest survival in HER2-ampliﬁed
cases and TOP2A aberrations did not affect this.
Table 2 Number of positive and negative cases for each marker
IHC (%) TOP2A normal TOP2A amplified TOP2A loss Total
HER2+ 72 (11.9) 32 (78.1) 6 (24.0) 110 (16.4)
HER2− 532 (88.1) 9 (21.9) 19 (76.0) 560 (83.6)
ER+ 500 (82.8) 31 (75.6) 17 (68.0) 548 (81.8)
ER− 102 (16.9) 10 (24.4) 8 (32.0) 120 (17.9)
PR+ 361 (59.8) 19 (46.3) 5 (20.0) 385 (57.5)
PR− 243 (40.2) 22 (53.7) 20 (80.0) 285 (42.5)
Ki67 >15% 270 (44.7) 24 (58.5) 13 (52.0) 307 (45.8)
Ki67 >15% 333 (55.1) 17 (41.5) 12 (48.0) 362 (54.0)
CK5+ 115 (19.0) 9 (21.9) 5 (20.0) 129 (19.3)
CK5− 489 (81.0) 32 (78.1) 20 (80.0) 541 (80.8)
EGFR+ 46 (7.6) 1 (2.4) 3 (12.0) 50 (7.5)
EGFR− 558 (92.4) 40 (97.6) 22 (88.0) 620 (92.5)
Total 604 (90.2) 41 (6.1) 25 (3.7) 670 (100.0)
ER, oestrogen receptor; PR, progesterone receptor.
Figure 2 Kaplan–Meier plot. Breast cancer-speciﬁc survival (BCSS)
according to TOP2A. p Value from log-rank test of differences in BCSS
ﬁrst 5 years after diagnosis was 0.02. After 5 years, the p value was
0.4.
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Risk of death from breast cancer, TOP2A, HER2 and HR
status
During the ﬁrst 5 years, risk of death from breast cancer appears
to be signiﬁcantly higher in cases with ampliﬁcation of TOP2A
and HER2 when analysed separately. When compared with no
ampliﬁcation for TOP2A and HER2, respectively, the HR for
TOP2A ampliﬁcation was 2.03 (95% CI 1.22 to 3.360) and for
HER2 was 2.77 (95% CI 1.97 to 3.89). Adjusting for age and
stage did not change the results. For those who survived the ﬁrst
5 years after diagnosis, there were no statistically signiﬁcant dif-
ferences in survival according to gene ampliﬁcation status.
However, as shown in table 3 and ﬁgure 4, TOP2A did not
exert an independent effect on prognosis. Adjusting for HR
status in the Cox proportional hazards model did not change
the results (data not shown). During the ﬁrst 5 years after diag-
nosis, the risk of death from breast cancer was signiﬁcantly
higher for HR+ cases with HER2 ampliﬁcation irrespective of
TOP2A status. Among the HR− cases, the numbers in each cat-
egory were low and the results must be interpreted with
caution.
DISCUSSION
TOP2A gene copy number change in breast cancer is an infre-
quent ﬁnding and its signiﬁcance has been difﬁcult to establish.
In this study of 670 cases of breast cancer with long-term
follow-up, the number of cases with TOP2A ampliﬁcation or
loss was far lower than the number of HER2-positive cases.
However, there was a large proportion of co-ampliﬁcation. In
contrast to others who have found that ampliﬁcation of one or
both genes entails a poorer prognosis compared with cases with
no ampliﬁcation,11 13 14 this study demonstrates that
Figure 3 Kaplan–Meier plot. Breast cancer-speciﬁc survival (BCSS)
according to HER2. p Value from log-rank test of differences in BCSS
ﬁrst 5 years after diagnosis was <0.0001. After 5 years, the p value
was 0.9.
Table 3 Risk of death from breast cancer according to TOP2A and HER2 amplification
Number of cases
Deaths from
breast cancer
Hazard ratio 95% CI
unadjusted
Hazard ratio 95% CI
adjusted for age
Hazard ratio 95% CI
adjusted for stage
TOP2A
Follow-up first 5 years after diagnosis 604 132 1.00 1.00 1.00
Not amplified 41 17 2.03 1.22 to 3.36 2.07 1.24 to 3.47 2.11 1.27 to 3.50
Amplified 25 5 0.91 0.37 to 2.21 0.82 0.33 to 2.01 0.70 0.29 to 1.73
Loss 670 154
TOP2A
Follow-up from 5 years after diagnosis* 359 87 1.00 1.00 1.00
Not amplified 22 5 0.75 0.30 to 1.85 0.74 0.30 to 1.86 1.02 0.41 to 2.54
Amplified 15 5 1.63 0.66 to 4.03 1.93 0.77 to 4.84 1.41 0.56 to 3.52
Loss 396 97
HER2
Follow-up first 5 years after diagnosis 560 105 1.00 1.00 1.00
Not amplified 110 49 2.77 1.97 to 3.89 2.81 1.95 to 4.04 2.66 1.89 to 3.75
Amplified 670 154
HER2
Follow-up from 5 years after diagnosis* 346 83 1.00 1.00 1.00
Not amplified 50 14 0.95 0.54 to 1.67 0.95 0.52 to 1.73 1.04 0.60 to 1.86
Amplified 396 97
HER2 and TOP2A
Follow-up first 5 years after diagnosis 532 100 1.00 1.00 1.00
Normal TOP2A and HER2 38 17 2.61 1.56 to 4.36 2.76 1.63 to 4.69 2.68 1.60 to 4.51
TOP2A change and HER2 amplification 28 5 0.96 0.39 to 2.37 0.89 0.36 to 2.21 0.77 0.31 to 1.90
TOP2A change and HER2 normal 72 32 2.86 1.92 to 4.26 2.81 1.84 to 4.29 2.59 1.74 to 3.87
Amplified HER2, TOP2A normal 670 154
HER2 and TOP2A
Follow-up from 5 years after diagnosis* 328 79 1.00 1.00 1.00
Normal TOP2A and HER2 19 6 0.99 0.43 to 2.28 0.97 0.41 to 2.28 1.44 0.62 to 3.37
TOP2A change and HER2 amplification 18 4 1.07 0.39 to 2.94 1.26 0.45 to 3.50 0.91 0.33 to 2.51
TOP2A change and HER2 normal 31 8 0.92 0.45 to 1.91 0.95 0.44 to 2.04 0.84 0.40 to 1.79
Amplified HER2, TOP2A normal 396 97
*Conditional on surviving the first 5 years CI.
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associations between BCSS and TOP2A copy number change are
not independent of HER2 and HR status.
The most important ﬁnding in this study is the strong associ-
ation between TOP2A copy number change and HR and HER2
status. These markers are well established as prognostic and pre-
dictive factors, and are to a high degree decisive for treatment
after surgery. To the best of our knowledge, few studies have
been designed to examine the prognostic value of TOP2A,
though it has been shown that TOP2A ampliﬁcation affects
BCSS and risk of death from breast cancer15 and that TOP2A
may be a prognostic marker in ER+ breast cancer.14 16
However, when the analyses include HR and HER2 status, the
present study shows that TOP2A has no independent prognostic
impact. TOP2A may still have some modulating effects on prog-
nostication, but this is probably of limited beneﬁt in clinical
practice.
Twenty of twenty-ﬁve cases with TOP2A loss were PR−, and
of these, 12 were ER+. PR negativeness is a predictor of poor
prognosis and appears to be associated with TOP2A loss.
However, in this study, survival tended to be better in PR− cases
with loss of TOP2A compared with cases with normal or ampli-
ﬁed TOP2A (data not shown).
The proportion of ampliﬁcation and co-ampliﬁcation of
TOP2A and HER2 in breast cancer varies between studies.
HER2 ampliﬁcation is reported to be around 15%.2 For
TOP2A, ampliﬁcation varies from 5% to 19%.3 17 18 In
HER2-positive breast cancer, ampliﬁcation of TOP2A varies
from 25% to 42%.1 19 Both ampliﬁcation and deletion of
TOP2A in the absence of HER2 ampliﬁcation have been demon-
strated.3 20 In the present study, 29.1% of the HER2-ampliﬁed
cases were co-ampliﬁed with TOP2A. The proportion of TOP2A
positive tumours in this study was lower than in other studies.2
However, the frequency of HER2 ampliﬁcation is comparable
with others, and this weighs against methodological problems.
Furthermore, a short DNA probe for TOP2A was used to avoid
overlap with HER2.21 This may in part account for the low
number of TOP2A-ampliﬁed cases in this study compared with
previous studies and may reﬂect the true frequency of this
ﬁnding.
Assessment of loss should be carried out with caution in
histopathological sections because nuclear truncation may lead
to a falsely low estimation of copy number. The cut-off for amp-
liﬁcation is usually set at a gene/chromosome ratio of ≥2.0, and
for deletion the cut-off level ranges from 0.5 to 1.0.21 It is pos-
sible that monosomy may have an impact similar to loss of indi-
vidual genes, but this is uncertain. In this study, only four cases
showed deletion and monosomy and deletion were grouped
together.
HER2-positive breast cancer has been shown to be more
aggressive than HER2–negative breast cancer. Co-ampliﬁcation
with other genes, such as STARD3 and GRB7, may contribute to
and possibly strengthen this aggressive behaviour.2 The propor-
tion of ampliﬁcation and co-ampliﬁcation of TOP2A and HER2
in breast cancer is low, and even in a series of 670 patients, the
numbers are too low to draw reliable conclusions. As a prognos-
tic marker, TOP2A is probably of limited value. TOP2A aberra-
tions are strongly associated with HR and HER2 status, and the
importance of these markers in prognostication is still
unchallenged.
Take-home messages
▸ TOP2A gene copy number change is an infrequent ﬁnding in
breast cancer.
▸ There is a strong association between TOP2A copy number
change and hormone receptor and HER2 status.
▸ As a prognostic marker, TOP2A is probably of limited value,
and hormone receptor and HER2 status remain
unchallenged.
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Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin
and molecular subtypes
Aims: The aim of this study was to compare breast
cancer speciﬁc survival (BCSS) for invasive lobular
carcinoma (ILC) and invasive ductal carcinoma (IDC)
and, further, to evaluate critically the prognostic
value of histopathological grading of ILC and examine
E-cadherin as a prognostic marker in ILC.
Methods and results: The study comprised 116 lobu-
lar and 611 ductal breast carcinomas occurring
between 1961 and 2008. All cases had been classi-
ﬁed previously according to histopathological type
and grade, stained for oestrogen receptor (ER),
progesterone receptor (PR), antigen Ki67 (Ki67),
epithelial growth factor receptor (EGFR), cytokeratin
5 (CK5) and human epidermal growth factor recep-
tor 2 (HER2) and classiﬁed into molecular subtypes.
For the present study, immunohistochemical stain-
ing for E-cadherin was performed. The Kaplan–
Meier method and Cox proportional hazards models
were used in the analyses. Grade 2 tumours com-
prised 85.3% of the lobular tumours and 51.9% of
the ductal tumours. BCSS in ILC grade 2 was com-
parable to that of IDC grade 3. E-cadherin-negative
ILC had a poorer prognosis compared to E-cadherin
positive ILC and to IDC regardless of E-cadherin
status.
Conclusions: The implication of histopathological
grading may differ in ILC compared to IDC. E-cadher-
in may be useful in prognostication in ILC and
thereby inﬂuence the determination of treatment
strategies for this group of women.
Keywords: breast cancer, breast cancer-speciﬁc survival, E-cadherin, histopathological grade, invasive lobular
carcinoma, prognosis
Introduction
Invasive lobular carcinoma (ILC) is deﬁned as an
invasive carcinoma comprising non-cohesive cells dis-
persed individually in a single-ﬁle linear pattern in a
ﬁbrous stroma and accounts for 5–15% of breast can-
cers.1–3 A number of variants of ILC do not show the
classical morphological pattern, but loss of cell-to-cell
cohesion is a common feature.3
Histopathological grade is an important prognostic
tool.4–6 The Nottingham grading system classiﬁes
patients into groups with different prognoses.7 How-
ever, in ILC the suitability of grading is uncertain.8,9
Glandular structures are absent, mitoses are infre-
quent and the nuclei uniform. Thus, most ILCs are
grade 2 and the prognostic value of grading is
unclear.
Breast cancer treatment guidelines are based on
hormone receptor, human epidermal growth factor
receptor 2 (HER2) and proliferation (Ki67) status, in
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addition to histopathological grade, tumour size and
lymph node status.10 Histopathological type is not
always included as a parameter in treatment guide-
lines, although favourable types may inﬂuence the
choice of treatment.
E-cadherin (E-cad) is a transmembrane protein
involved in cell-to-cell adhesion, and its loss promotes
invasion and metastasis.11 Loss of E-cad is common
in ILC,11,12 and supports the diagnosis of ILC.13
Although it has been suggested that low levels of
E-cad are associated with poorer prognosis,14–16 its
potential as a prognostic marker in ILC has not been
clariﬁed.
The aims of this study were to compare breast can-
cer-speciﬁc survival (BCSS) in ILC with invasive duc-
tal carcinoma (IDC) in a cohort of breast cancer
patients with a long follow-up, to assess the prognos-
tic value of histopathological grading of ILC and to
examine the potential of E-cad as a prognostic marker
in ILC.
Material and methods
S T U D Y P O P U L A T I O N
Between 1956 and 1959, women from Nord Trønde-
lag County in Norway were invited by the Norwegian
Cancer Registry to participate in a breast cancer sur-
vey. The population has been described previ-
ously.17,18 Brieﬂy, 25 897 women, born between
1886 and 1928, were invited. From 1961 to 2008,
1393 women developed breast cancer. Cases occur-
ring prior to 1961 were excluded. A total of 945 tis-
sue samples were available at the Department of
Pathology and Medical Genetics, St Olav’s Hospital,
Trondheim, Norway, and 867 were suitable for inclu-
sion in tissue microarrays (TMA). After linkage with
the Cause of Death Registry of Norway and the Nor-
wegian Cancer Registry, survival data were gener-
ated. Only cases of IDC of no special type and ILC
(727 cases) were included in the present study.
S P E C I M E N C H A R A C T E R I S T I C S
All cases were classiﬁed into histopathological type
and grade and reclassiﬁed into molecular subtypes
using surrogate markers for gene expression analyses
(Figure 1).17 Histopathological typing and grading
was performed independently on full-face sections by
two experienced pathologists (O.A.H., A.M.B.).3,5,19
Three 1-mm tissue cores from the periphery of each
tumour were selected and assembled in TMAs. Immu-
nohistochemical (IHC) staining was performed for
oestrogen receptor (ER), progesterone receptor (PR),
antigen Ki67 (Ki67), HER2, cytokeratin 5 (CK5) and
epithelial growth factor receptor 1 (EGFR). HER2
gene ampliﬁcation status was estimated using chro-
mogenic in-situ hybridization (CISH). For the present
study, IHC staining was performed for E-cad.
A S S A Y M E T H O D S
Assay methods for all markers except E-cad have
been described in detail previously.17 For the present
study, IHC for detection of E-cad was performed
according to the manufacturer’s guidelines (Dako,
Glostrup, Denmark). The sections were mounted on
Superfrost+ glass slides, dried at 37°C overnight and
stored at 20°C. Before staining, the slides were
heated to 60°C for 2 h and pretreated in a PT Link
pretreatment module for tissue specimens (Dako) with
buffer (high pH target retrieval solution K8004) at
97°C for 20 min. Monoclonal mouse antibody (clone
NCH-38), 55.2 mg/l dilution 1:100, was applied. For
visualization, the Dako REALTM EnVisionTM detection
system was used with peroxidase/diaminobenzidine
(DAB)+, rabbit/mouse, code K5007.
S C O R I N G A N D R E P O R T I N G
The REMARK reporting recommendations for tumour
marker studies were followed.20 All IHC evaluations
were performed independently by two researchers. ER
and PR were positive if ≥1% of the tumour cells
showed positive nuclear staining. For Ki67, ≥15%
stained nuclei was classiﬁed as Ki67high and <15% as
Ki67low. A staining index (SI) (intensity 9 propor-
tion) was calculated for CK5 and EGFR; SI of 0–1
was considered to be negative and 2–9 was consid-
ered to be positive, as described previously. HER2
gene ampliﬁcation was deﬁned as gene to chromo-
some ratio ≥2. In cases where CISH failed, +3 IHC
staining for HER2 was recorded as positive.17 In the
HER2–
Luminal A
Luminal B
(HER2–)
Luminal B
(HER2+)
HER2 type
5 Negative
Phenotype
Basal
Phenotype
All tumours
Ki67<15%
Κι67≥15%ER+and/or
PR+
HER2–
CK5–and
EGFR–
CK5+and/or
EGFR+
HER2+
ER –and
PR –
HER2+
Figure 1. Classiﬁcation algorithm for molecular subtyping.17
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present study, only moderate or strong continuous
membrane staining for E-cad in >50% of tumour cells
were classiﬁed as positive. There were very few cases
with aberrant staining (cytoplasmic staining or inter-
mittent membranous staining), and these were classi-
ﬁed as negative.
S T A T I S T I C A L A N A L Y S E S
Follow-up was from date of diagnosis until death or
31 December 2010. Kaplan–Meier methods were
used to estimate BCSS for ILC grade 2 compared to
IDC grades 1, 2 and 3, and for comparing survival of
ILC and IDC grade 2, E-cad+ and E-cad tumours.
Grade 2 ILC and IDC were compared for each of the
following biomarker categories separately: ER+,
Ki67low and HER2. Comparison was made between
ILC and IDC grade 2 tumours with the favourable bi-
omarker proﬁle (ER+ and HER2 and Ki67low). BCSS
for luminal A and luminal B (HER2) subtypes were
compared for ILC and IDC separately. The log-rank
test was used to compare survival curves, P < 0.05
was considered statistically signiﬁcant. Cox propor-
tional hazards models were used to estimate relative
risks of death from breast cancer adjusted for age (5-
year intervals), stage at diagnosis (I, II, III, IV,
unknown) and time-period of diagnosis. Hazard ratios
(HR) for ILC compared to IDC were calculated with
95% conﬁdence intervals (CI). The numbers of cases
of ILC grades 1 and 3 were too low for reliable analy-
ses of grade and BCSS in ILC. The number of cases
with an unfavourable biomarker proﬁle (ER, HER2+
and Ki67high) was too small for separate analysis
(n = 39). Statistical analyses were performed using
Stata version 12.1 (Stata Corp., College Station, TX,
USA).
E T H I C S
Approval was granted by the Regional Committee for
Medical and Health Sciences Research Ethics, includ-
ing dispensation from the requirement of patient con-
sent (REK, Midt-Norge, ref. no. 836/2009).
Results
D E S C R I P T I O N O F T H E P O P U L A T I O N
Of the 727 cases, 16% were ILC and 84% were IDC
(Table 1). During follow-up, 297 (40.9%) died from
breast cancer and 304 (41.8%) died of other causes.
At the end of the period, 126 (17.3%) were still alive.
Mean age at diagnosis was 71.3 years for IDC and
73.3 years for ILC. Table 2 shows the treatments
given.
T U M O U R C H A R A C T E R I S T I C S
Histopathological grade, tumour size, lymph node sta-
tus, stage and molecular subtypes are given in
Table 1. Table 3 shows the results of IHC and CISH.
The proportion of histopathological grade 2 tumours
was higher in ILC (85.3%) compared to IDC (51.9%).
In ILC 87.9% were ER+ and 6.0% were HER2+, com-
pared to 83.6% ER+ and 16.9% HER2+ in IDC. A
higher proportion of ILC (16.4%) than IDC (7.5%)
were >5 cm. However, the proportions of tumours
between 2 and 5 cm were similar (42.2 versus
45.5%).
G R A D E , T Y P E A N D P R O G N O S I S
Figure 2 shows BCSS for ILC grade 2 compared to
IDC grades 1, 2 and 3. ILC grade 2 had poorer BCSS
compared to IDC grade 2 (P = 0.01, log-rank test).-
There was no signiﬁcant difference in BCSS between
ILC grade 2 and IDC grade 3 (P = 0.48, log-rank
test). Table 4 shows the risk of death from breast
cancer according to type. ILC grade 2 was compared
to IDC grades 1, 2 and 3 separately. HRs were similar
for ILC grade 2 and IDC grade 3, whereas IDC grade
2 had a signiﬁcantly better survival than ILC grade 2
(HR: 0.66, 95% CI: 0.46–0.94). Adjustment for age,
stage and time of diagnosis did not inﬂuence the
results.
P R O G N O S T I C V A L U E O F T Y P E I N E R + , H E R 2  A N D
K I 6 7 L O W T U M O U R S
Table 5 shows risk of death from breast cancer
according to type among patients with grade 2
tumours and clinically favourable biomarker proﬁles.
For each marker status (ER+, HER2, Ki67low),
respectively, there was a signiﬁcantly higher risk of
death from ILC compared to IDC. Similarly, risk of
death from breast cancer for patients with grade 2
tumours expressing a complete favourable biomarker
proﬁle (ER+, HER2 and Ki67low) was higher for ILC
than for IDC (HR: 2.16, 95% CI: 1.34–3.49). Analy-
sis of all grades did not alter the results (data not
shown).
P R O G N O S T I C V A L U E O F M O L E C U L A R S U B T Y P E S
The proportions of HER2+ and/or ER ILC were low
compared to IDC, as reﬂected in the distribution
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of molecular subtypes (Table 1). Among 353 lumi-
nal A cases, 290 (82.2%) were ductal and 63
(17.8%) were lobular. Figure 3 shows that luminal
A ILC had a poorer prognosis than luminal A IDC
(P = 0.02, log-rank test). Luminal B (HER2) IDC
had a slightly better prognosis than luminal A and
luminal B (HER2) ILC (P = 0.39, log-rank test).
Table 6 shows that risk of death from grade 2
Table 1. Summary of patient and tumour characteristics
Patient and tumour characteristics Ductal Lobular Total
Number (%) 611 (84.0) 116 (16.0) 727 (100.0)
Number of breast cancer deaths (%) 246 (40.3) 51 (44.0) 297 (40.9)
Mean age at diagnosis (SD) 71.3 (10.7) 73.3 (9.1) 71.7 (10.5)
Median years of follow-up after diagnosis (IQR) 7.2 (10.6) 4.8 (7.9) 6.8 (10.4)
Tumour grade (%)
1 61 (10.0) 9 (7.8) 70 (9.6)
2 317 (51.9) 99 (85.3) 416 (57.2)
3 233 (38.1) 8 (6.9) 241 (33.2)
Tumour size (%)
≤2 cm 182 (29.8) 20 (17.2) 202 (27.8)
>2 cm, ≤5 cm 221 (36.2) 43 (37.1) 264 (36.3)
>5 cm 46 (7.5) 19 (16.4) 65 (8.9)
Uncertain 162 (26.1) 34 (29.3) 196 (27.0)
Lymph node status
No metastasis 234 (38.3) 45 (38.8) 279 (38.4)
Metastasis detected 236 (38.6) 38 (32.8) 274 (37.7)
Not examined for metastasis 141 (23.1) 33 (28.4) 174 (23.9)
Stage at diagnosis
Stage I 294 (48.1) 52 (44.8) 346 (47.6)
Stage II 246 (40.3) 49 (42.2) 295 (40.6)
Stage III 37 (6.1) 11 (9.5) 48 (6.6)
Stage IV 29 (4.8) 4 (3.5) 33 (4.5)
Stage uncertain 5 (0.8) 0 5 (0.7)
Molecular subtypes (%)
Luminal A 290 (47.5) 63 (54.3) 353 (48.6)
Luminal B (HER2) 170 (27.8) 33 (28.5) 203 (27.9)
Luminal B (HER2+) 54 (8.8) 6 (5.2) 60 (8.3)
HER2 type 49 (8.0) 1 (0.9) 50 (6.9)
Five negative phenotype 13 (2.1) 11 (9.5) 24 (3.3)
Basal phenotype 35 (5.7) 2 (1.7) 37 (5.1)
SD, standard deviation; IQR, interquartile range; HER2, human epidermal growth factor receptor 2.
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Table 2. Summary of breast cancer therapies for all cases
Invasive ductal carcinoma
n = 611 (%)
Invasive lobular carcinoma
n = 116 (%)
Total
n = 727 (%)
Mastectomy 524 (85.8) 94 (81.0) 618 (85.0)
Breast conserving therapy 61 (10.0) 12 (10.4) 73 (10.0)
Only biopsy, no surgical treatment 26 (4.3) 10 (8.6) 36 (5.0)
Axillary surgery (clearance or sentinel node) 461 (75.5) 81 (69.9) 542 (74.6)
Hormone therapy* 134 (26.2**) 31 (30.4**) 165 (26.9**)
Trastuzumab 0 0 0
Chemotherapy Unknown Unknown Unknown
Radiation Unknown Unknown Unknown
*Estimated according to guidelines at diagnosis; **% of the hormone receptor-positive cases.
Table 3. Results of immunohistochemical and in-situ hybridization markers
Ductal
(n = 611)
Lobular
(n = 116)
Total
(n = 727)
ER+ 511 (83.6) 102 (87.9) 613 (84.3)
ER 98 (16.0) 14 (12.1) 112 (15.4)
Not possible to interpret 2 (0.3) 0 2 (0.3)
PR+ 364 (59.6) 58 (50.0) 422 (58.1)
PR 246 (40.3) 58 (50.0) 304 (41.8)
Not possible to interpret 1 (0.2) 0 1 (0.1)
HER2+ 103 (16.9) 7 (6.0) 110 (15.1)
HER2 508 (83.1) 109 (94.0) 617 (84.9)
Ki67high 280 (45.8) 39 (33.6) 319 (43.9)
Ki67low 330 (54.0) 77 (66.4) 407 (56.0)
Not possible to interpret 1 (0.2) 0 1 (0.1)
CK5+ 120 (19.6) 4 (3.5) 124 (17.1)
CK5 491 (80.4) 112 (96.6) 603 (82.9)
EGFR+ 41 (6.7) 3 (2.6) 44 (6.1)
EGFR 570 (93.3) 113 (97.4) 683 (93.9)
E-cad+ 523 (85.6) 27 (23.3) 550 (75.7)
E-cad 69 (11.3) 86 (74.1) 155 (21.3)
Not possible to interpret 19 (3.1) 3 (2.6) 22 (3.0)
EGFR, epithelial growth factor receptor; ER, oestrogen receptor; PR, progesterone receptor.
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breast cancer was higher for luminal A ILC, lumi-
nal B (HER2) ILC and luminal B (HER2) IDC
compared to luminal A IDC. The difference between
luminal A IDC and ILC was statistically signiﬁcant.
The numbers in the other subtypes were too low
for analysis.
P R O G N O S T I C V A L U E O F E - C A D H E R I N
Table 3 shows that 23.3% of ILC were E-cad+.
Figure 4 shows BCSS for grade 2 E-cad+ and E-cad
ILC and IDC. E-cad ILC had poorer prognosis than
E-cad+ ILC (P = 0.005, log-rank test). Figure 5 shows
examples of E-cad IHC staining. Table 7 shows that
risk of death from breast cancer for ILC E-cad was
nearly twofold (HR: 1.96, 95% CI: 1.32–2.89) com-
pared to IDC E-cad+. There was no clear difference in
prognosis between IDC E-cad+, IDC E-cad and ILC
E-cad+. Adjustment for age, stage and time-period did
not inﬂuence the results.
Discussion
The main ﬁnding in this study of a cohort of breast
cancer patients with long-term follow-up was a signif-
icantly poorer prognosis for grade 2 ILC compared to
grade 2 IDC. The prognosis for grade 2 ILC was com-
parable to that of grade 3 IDC. A similar pattern was
observed when the analyses were restricted to
tumours with positive prognostic marker proﬁles
(ER+, HER2 and Ki67low). Furthermore, E-cad
expression appeared to be a favourable prognostic
marker in ILC.
In the Nottingham grading system gland forma-
tion, nuclear atypia/pleomorphism and mitosis counts
are considered.5 However, because the morphological
features of ILC differ from IDC, grade may have a dif-
ferent prognostic signiﬁcance.8,21 This is an impor-
tant discussion, because histopathological grade is
one of several factors determining adjuvant therapy,
whereas type is disregarded.
In agreement with others,1,21,22 there were few
ILCs of grade 1 (7.8%) and grade 3 (6.9%) in this
study, and the low numbers preclude survival analy-
ses. Histopathological grading has been shown to be
of independent prognostic value in ILC.23 However,
the implications of grading in ILC may differ from
IDC and its value as a prognostic tool must be consid-
ered in this light, particularly when determining
treatment strategies.
ER, HER2 and Ki67 are important prognostic and/
or predictive markers. In this study, the proportion of
ILCs with a favourable marker proﬁle was higher
Table 4. Risk of death from breast cancer. Invasive lobular carcinoma grade 2 compared to invasive ductal carcinoma
grades 1, 2 and 3
Tumour
characteristics
Number
of cases
Deaths
from
breast
cancer
HR 95%CI HR 95%CI HR 95%CI HR 95%CI
Unadjusted Adjusted for age
Adjusted for
stage
Adjusted for time
period of
diagnosis (10-
year intervals)
Lobular grade 2 99 42 1.00 1.00 1.00 1.00
Ductal grade 1 61 17 0.43 0.24–0.75 0.47 0.27–0.84 0.49 0.28–0.87 0.40 0.23–0.71
Ductal grade 2 317 114 0.66 0.46–0.94 0.67 0.47–0.95 0.59 0.41–0.85 0.66 0.46–0.94
Ductal grade 3 233 115 1.10 0.77–1.56 1.13 0.79–1.61 1.10 0.77–1.57 1.03 0.72–1.47
710 297
HR, hazard ratio; CI, conﬁdence interval.
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Figure 2. Breast cancer speciﬁc survival for invasive lobular carci-
noma grade 2 compared to ductal carcinoma grades 1, 2 and 3.
P-value from log-rank test of differences in breast cancer speciﬁc
survival (BCSS) was 0.01.
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compared to IDC, implying a better prognosis for ILC.
However, even when restricting analyses to cases
with favourable marker proﬁles, a signiﬁcantly poorer
prognosis was found in ILC compared to IDC. HER2+
cases in ILC were few (Table 2), thus limiting its util-
ity as a prognostic marker in ILC. Better prognostic
markers for ILC are required.
In this study, E-cad+ grade 2 ILC was prognostical-
ly comparable to grade 2 IDC (both E-cad+ and
E-cad). E-cad- ILC had a poorer prognosis. The iden-
tiﬁcation of patients with ILC of expected poor prog-
nosis may have implications when determining
adjuvant therapy. If the prognostic utility of E-cad for
ILC is conﬁrmed in future studies and robust guide-
lines for interpretation of E-cad IHC are devel-
oped,14,15 this could extend the use of a well-known
marker for the beneﬁt of a substantial proportion of
breast cancer patients.
The loss of E-cad expression is shown to promote
invasion and metastasis of epithelial cancers, includ-
ing breast cancer.24 E-cad may be involved in other
cellular processes of importance as a tumour suppres-
sor gene.25 Cell-to-cell adhesion involves cytoplasmic
catenins and the actin cytoskeleton in addition to
Table 5. Risk of death from invasive lobular grade 2 compared to invasive ductal carcinoma grade 2
Tumour
characteristics
Number
of cases
Deaths
from
breast
cancer
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Unadjusted Adjusted for age Adjusted for stage
Adjusted for
time period of
diagnosis (10-
year intervals)
ER+
Ductal 297 100 1.00 1.00 1.00 1.00
Lobular 88 37 1.71 1.17–2.50 1.68 1.14–2.47 1.97 1.33–2.91 1.82 1.24–2.68
385 137
Ki67low
Ductal 224 71 1.00 1.00 1.00 1.00
Lobular 70 30 2.01 1.31–3.01 1.95 1.26–3.03 2.20 1.42–3.43 2.03 1.31–3.14
294 101
HER2
Ductal 287 97 1.00 1.00 1.00 1.00
Lobular 93 39 1.76 1.21–2.56 1.74 1.19–2.55 1.98 1.30–2.90 1.22–2.60 1.78 1.22–2.60
380 136
ER+, Ki67low and HER2
Ductal 201 61 1.00 1.00 1.00 1.00
Lobular 56 24 2.16 1.34–3.49 2.04 1.25–3.34 2.45 1.50–4.01 2.31 1.42–3.76
257 85
HR, hazard ratio; CI, conﬁdence interval; HER2, human epidermal growth factor receptor 2.
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Figure 3. Breast cancer speciﬁc survival for invasive lobular and
ductal carcinoma grade 2 according to luminal A and luminal B
[human epidermal growth factor receptor 2 (HER2)] subtypes.
P-value from log-rank test of differences in breast cancer speciﬁc
survival (BCSS) was 0.02.
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E-cad, and these mechanisms are complex.26 Loss of
tumour suppressor function and impaired cell-to-cell
adhesion, both of which are dependent in part on
E-cad, underline the importance of this molecule in
breast cancer.
The proportion of E-cad+ ILC reported varies from
0 to 20%.27–29 In this study, where histopathologi-
cal typing was based on morphology only, 23.3%
were E-cad+. No cases were revised according to
histopathological type in light of E-cad status. Mixed
lobular and ductal carcinomas are not infrequent.3 In
this study, mixed tumours were classiﬁed as duc-
tal.27,30,31
Molecular subtyping is based mainly on studies of
IDC.32 IDC is the most common histopathological
type, although type is rarely mentioned.33–35 For
other types, the prognostic value of molecular subtyp-
ing remains uncertain. In this study, there were too
few ILCs in the non-luminal and HER2 subtypes for
reliable results. However, the differences in BCSS in
the HER2 luminal subtypes between ILC and IDC
are comparable to the results of the biomarker analy-
ses. Considered together, the results conﬁrm that his-
topathological type has an independent impact in the
prognostication of ILC.
The main strength of this study is the historical
nature of the patient cohort enabling complete long-
term follow-up. The vast majority of women in this
study developed breast cancer in an era prior to the
use of hormonal contraception, menopausal hor-
monal therapy (MHT) and mammography screening,
and did not qualify for new therapies as they were
introduced, thus enabling insight into the near-natu-
ral course of this disease. A drawback is the relative
high age of the women, and should be considered
when interpreting the results. Others have shown
better,36 similar2,37 or poorer38,39 prognosis for ILC
compared to IDC. Differences in patient populations,
follow-up and adjuvant therapy may explain these
inconsistencies. Some studies have shown an
increased risk of ILC when using MHT.40–42 It is
unclear whether or not there are differences in prog-
nosis between MHT-associated ILC and ILC in non-
users.43 The majority of cancers in the present study
were diagnosed in a time-period or at an age when
MHT was rarely used.
In this study, 99 of 116 ILCs were histopathologi-
cal grade 2. The numbers of grades 1 and 3 were
low, and this can be attributed to the morphological
features of ILC. This impairs grading as a prognostic
Table 6. Risk of death from invasive lobular carcinoma grade 2 and invasive ductal carcinoma grade 2 according to luminal
A and luminal B (HER2) subtypes
Number
of cases
Deaths
from
breast
cancer
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Unadjusted Adjusted for age
Adjusted for
stage
Adjusted for
time-period of
diagnosis (10-
year intervals)
Ductal luminal A 203 62 1.00 1.00 1.00 1.00
Ductal luminal B (HER2) 74 29 1.48 0.95–2.31 1.55 0.99–2.42 1.70 1.09–2.67 1.36 0.87–2.12
Lobular luminal A 56 24 2.11 1.31–3.39 2.08 1.28–3.38 2.53 1.55–4.12 2.21 1.36–3.57
Lobular luminal B (HER2) 26 10 1.78 0.91–3.48 1.81 0.92–3.57 2.10 1.07–4.14 1.74 0.88–3.41
359 125
HR, hazard ratio; CI, conﬁdence interval; HER2, human epidermal growth factor receptor 2.
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Figure 4. Breast cancer speciﬁc survival for for invasive lobular
and ductal carcinoma grade 2 according to E-cadherin status. P-
value from log-rank test of differences in breast cancer speciﬁc sur-
vival (BCSS) was 0.005.
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tool in ILC. Similarly, the prognostic value of HER2
in ILC may be limited due to the low number of ILCs
expressing HER2. However, grade 2 ILC had a consis-
tently poorer prognosis when compared to grade 2
IDC, and the differences were also apparent when the
analyses included only tumours with presumed
favourable biomarkers. Due to the low number of lob-
ular tumours in our study, we did not have sufﬁcient
statistical power to investigate the prognostic value of
an unfavourable biomarker proﬁle within lobular
cancers. The present study supports the claim that
lobular lesions are a distinct family of neoplastic
lesions in the breast.12 The role of E-cad in ILC may
not only be in the determination of histopathological
type; it may also be more useful than grade in prog-
nostication and in the determination of treatment.
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year intervals)
Ductal, E-cad+ 260 94 1.00 1.00 1.00 1.00
Ductal, E-cad 46 16 1.03 0.61–1.75 1.00 0.59–1.71 1.17 0.68–2.00 1.03 0.60–1.76
Lobular, E-cad+ 24 7 0.84 0.39–1.81 0.86 0.40–1.88 0.87 0.40–1.89 0.83 0.38–1.79
Lobular, E-cad 74 35 1.96 1.32–2.89 1.88 1.27–2.80 2.30 1.54–3.44 2.03 1.36–3.01
404 152
HR, hazard ratio; CI, conﬁdence interval.
© 2014 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
Prognostication in lobular breast cancer 9
The authors thank the Department of Pathology and
Medical Genetics, St Olav’s Hospital for making the
archives available for the study, the Cancer Registry
of Norway for providing the patient data and senior
biomedical scientist Borgny Ytterhus for her invalu-
able work in the laboratory.
Conﬂicts of interest
The authors declare that they have no competing
interests.
References
1. Rakha EA, El-Sayed ME, Powe DG et al. Invasive lobular carci-
noma of the breast: response to hormonal therapy and out-
comes. Eur. J. Cancer 2008; 44; 73–83.
2. Arpino G, Bardou VJ, Clark GM, Elledge RM. Inﬁltrating lobular
carcinoma of the breast: tumor characteristics and clinical out-
come. Breast Cancer Res. 2004; 6; R149–R156.
3. Lakhani SR, Ellis I, Schnitt SJ, Tan PH, Van de Vijver M, World
Health Organization (eds). WHO classiﬁcation of tumours of the
breast. Lyon: International Agency for Research on Cancer
(IARC), 2012.
4. Bloom HJ, Richardson WW. Histological grading and prognosis
in breast cancer; a study of 1409 cases of which 359 have
been followed for 15 years. Br. J. Cancer 1957; 11; 359–377.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer:
experience from a large study with long-term follow-up. Histo-
pathology 1991; 19; 403–410.
6. Rakha EA, Reis-Filho JS, Baehner F et al. Breast cancer prog-
nostic classiﬁcation in the molecular era: the role of histological
grade. Breast Cancer Res. 2010; 12; 207.
7. Rakha EA, El-Sayed ME, Lee AH et al. Prognostic signiﬁcance
of Nottingham histologic grade in invasive breast carcinoma. J.
Clin. Oncol. 2008; 26; 3153–3158.
8. Wachtel MS, Halldorsson A, Dissanaike S. Nottingham grades
of lobular carcinoma lack the prognostic implications they bear
for ductal carcinoma. J. Surg. Res. 2011; 166; 19–27.
9. Bane AL, Tjan S, Parkes RK, Andrulis I, O’Malley FP. Invasive
lobular carcinoma: To grade or not to grade. Mod. Pathol.
2005; 18; 621–628.
10. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treat-
ment of women with early breast cancer: highlights of the St
Gallen international expert consensus on the primary therapy of
early breast cancer 2013. Ann. Oncol. 2013; 24; 2206–2223.
11. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction
of e-cadherin expression is associated with non-lobular breast
carcinomas of basal-like and triple negative phenotype. J. Clin.
Pathol. 2008; 61; 615–620.
12. Dabbs DJ, Schnitt SJ, Geyer FC et al. Lobular neoplasia of the
breast revisited with emphasis on the role of e-cadherin immu-
nohistochemistry. Am. J. Surg. Pathol. 2013; 37; e1–e11.
13. Oliveira TM, Elias J Jr, Melo AF et al. Evolving concepts in
breast lobular neoplasia and invasive lobular carcinoma, and
their impact on imaging methods. Insights Imaging 2014; 5;
183–194.
14. Brzozowska A, Sodolski T, Duma D, Mazurkiewicz T, Mazur-
kiewicz M. Evaluation of prognostic parameters of e-cadherin
status in breast cancer treatment. Ann. Agric. Environ. Med.
2012; 19; 541–546.
15. Younis LK, El Sakka H, Haque I. The prognostic value of
e-cadherin expression in breast cancer. Int. J. Health Sci. (Qas-
sim) 2007; 1; 43–51.
16. Saadatmand S, de Kruijf EM, Sajet A et al. Expression of cell
adhesion molecules and prognosis in breast cancer. Br. J. Surg.
2013; 100; 252–260.
17. Engstrom MJ, Opdahl S, Hagen AI et al. Molecular subtypes,
histopathological grade and survival in a historic cohort of
breast cancer patients. Breast Cancer Res. Treat. 2013; 140;
463–473.
18. Kvale G, Heuch I, Eide G. A prospective study of reproductive
factors and breast cancer. Am. J. Epidemiol. 1987; 126; 831–
841.
19. Robbins P, Pinder S, de Klerk N et al. Histological grading of
breast carcinomas: a study of interobserver agreement. Hum.
Pathol. 1995; 26; 873–879.
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M,
Clark GM. Reporting recommendations for tumor marker prog-
nostic studies (remark). Breast Cancer Res. Treat. 2006; 100;
229–235.
21. Sinha PS, Bendall S, Bates T. Does routine grading of invasive
lobular cancer of the breast have the same prognostic signiﬁ-
cance as for ductal cancers? Eur. J. Surg. Oncol. 2000; 26;
733–737.
22. Talman ML, Jensen MB, Rank F. Invasive lobular breast can-
cer. Prognostic signiﬁcance of histological malignancy grading.
Acta Oncol. 2007; 46; 803–809.
23. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO.
Histologic grading is an independent prognostic factor in inva-
sive lobular carcinoma of the breast. Breast Cancer Res. Treat.
2008; 111; 121–127.
24. Gould Rothberg BE, Bracken MB. E-cadherin immunohisto-
chemical expression as a prognostic factor in inﬁltrating
ductal carcinoma of the breast: a systematic review and
meta-analysis. Breast Cancer Res. Treat. 2006; 100; 139–
148.
25. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO.
E-cadherin expression in invasive non-lobular carcinoma of the
breast and its prognostic signiﬁcance. Histopathology 2005; 46;
685–693.
26. Morrogh M, Andrade VP, Giri D et al. Cadherin–catenin com-
plex dissociation in lobular neoplasia of the breast. Breast Can-
cer Res. Treat. 2012; 132; 641–652.
27. Kuroda H, Tamaru J, Takeuchi I et al. Expression of e-cadher-
in, alpha-catenin, and beta-catenin in tubulolobular carcinoma
of the breast. Virchows Arch. 2006; 448; 500–505.
28. Szasz AM, Nemeth Z, Gyorffy B et al. Identiﬁcation of a clau-
din-4 and e-cadherin score to predict prognosis in breast can-
cer. Cancer Sci. 2011; 102; 2248–2254.
29. Rakha EA, Patel A, Powe DG et al. Clinical and biological sig-
niﬁcance of e-cadherin protein expression in invasive lobular
carcinoma of the breast. Am. J. Surg. Pathol. 2010; 34; 1472–
1479.
30. Wheeler DT, Tai LH, Bratthauer GL, Waldner DL, Tavassoli
FA. Tubulolobular carcinoma of the breast: an analysis of 27
cases of a tumor with a hybrid morphology and immunopro-
ﬁle. Am. J. Surg. Pathol. 2004; 28; 1587–1593.
31. Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic
expression of the e-cadherin/catenin complex in tubulolobular
carcinoma of the breast: an immunohistochemical and clinico-
pathologic study. Mod. Pathol. 2007; 20; 130–138.
© 2014 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
10 M J Engstrøm et al.
32. Weigelt B, Horlings HM, Kreike B et al. Reﬁnement of breast
cancer classiﬁcation by molecular characterization of histologi-
cal special types. J. Pathol. 2008; 216; 141–150.
33. van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression
signature as a predictor of survival in breast cancer. N. Engl. J.
Med. 2002; 347; 1999–2009.
34. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast
tumors are conserved across microarray platforms. BMC Ge-
nom. 2006; 7; 96.
35. Wang Y, Klijn JG, Zhang Y et al. Gene-expression proﬁles to
predict distant metastasis of lymph-node-negative primary
breast cancer. Lancet 2005; 365; 671–679.
36. Toikkanen S, Pylkkanen L, Joensuu H. Invasive lobular carci-
noma of the breast has better short- and long-term survival
than invasive ductal carcinoma. Br. J. Cancer 1997; 76; 1234–
1240.
37. Li CI. Risk of mortality by histologic type of breast cancer in
the united states. Horm. Cancer 2010; 1; 156–165.
38. Pestalozzi BC, Zahrieh D, Mallon E et al. Distinct clinical and
prognostic features of inﬁltrating lobular carcinoma of the
breast: combined results of 15 international breast cancer
study group clinical trials. J. Clin. Oncol. 2008; 26; 3006–
3014.
39. Colleoni M, Rotmensz N, Maisonneuve P et al. Outcome of spe-
cial types of luminal breast cancer. Ann. Oncol. 2012; 23;
1428–1436.
40. Hein R, Flesch-Janys D, Dahmen N et al. A genome-wide associ-
ation study to identify genetic susceptibility loci that modify
ductal and lobular postmenopausal breast cancer risk associated
with menopausal hormone therapy use: a two-stage design
with replication. Breast Cancer Res. Treat. 2013; 138; 529–542.
41. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal
therapy for menopause and breast-cancer risk by histological
type: a cohort study and meta-analysis. Lancet Oncol. 2006; 7;
910–918.
42. Li CI, Daling JR, Haugen KL, Tang MT, Porter PL, Malone KE.
Use of menopausal hormone therapy and risk of ductal and
lobular breast cancer among women 55–74 years of age.
Breast Cancer Res. Treat. 2014; 145; 481–489.
43. Chlebowski RT, Anderson GL. Changing concepts: menopausal
hormone therapy and breast cancer. J. Natl Cancer Inst. 2012;
104; 517–527.
© 2014 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
Prognostication in lobular breast cancer 11
